COMMISSION STAFF WORKING DOCUMENT Accompanying the document Report from the Commission to the European Parliament and the Council Implementation of the third Programme of Union action in the field of health in 2019
Date: 2021-11-05
Institutions: Directorate-General for Health and Food Safety, European Commission
Subjects: EU programme, e-Health, health care, health care system, implementation of the budget, medical device, orphan disease, programme budgeting, vaccination

EN 

  EN 

   EUROPEAN COMMISSION  Brussels, 5.11.2021  SWD(2021) 311 final  COMMISSION STAFF WORKING DOCUMENT Accompanying the document Report from the Commission to the European Parliament and the Council Implementation of the third Programme of Union action in the field of health in 2019 {COM(2021) 680 final}  
 
 
Table of contents 
Introduction ............................................................................................................................................................... 3 

1. JOINT ACTIONS ................................................................................................................................................. 4 

1.1 Efficient response to highly dangerous and emerging pathogens at EU level (EMERGE) .................. 4 

1.2 Joint Action on Market Surveillance of Medical devices (JAMS) ....................................................... 6 

1.3  Vigilance  and  inspection  for  the  safety  of  transfusion  assisted  reproduction  and  transplantation 
(VISTART) ................................................................................................................................................. 7 

2. PROJECTS ......................................................................................................................................................... 10 

2.1  Raising  awareness  and  action-research  on  heavy  episodic  drinking  among  low-income  youth  and 
young adults in Southern Europe (AllCool) ............................................................................................. 10 

2.2 Operational refugee and migrant maternal approach (ORAMMA) .................................................... 11 

2.3  FRAILTOOLS:  a  comprehensive  validation  of  tools  to  screen  and  diagnose  frailty  in  different 
clinical and social settings to provide instruments for integrated care in older adults .............................. 13 

2.4 Scaling integrated care in context (SCIROCCO)................................................................................ 15 

2.5 Good practices for demonstrating safety and quality through recipient follow-up [Euro-GTP II] ..... 16 

3. OPERATING GRANTS ..................................................................................................................................... 18 

3.1 EUROPEAN PUBLIC HEALTH ALLIANCE .................................................................................. 19 

3.2 Health Action International (HAI) ...................................................................................................... 21 

3.3 EURORDIS......................................................................................................................................... 22 

4. DIRECT GRANT WITH INTERNATIONAL ORGANISATIONS ................................................................. 24 

4.1 Country Health Profiles 2019 (OECD and European Observatory on Health Systems and Policies); 
Health at a Glance: Europe 2020 (OECD) ................................................................................................ 24 

4.2 OECD- Support to develop patient-reported measures (PaRIS) ......................................................... 26 

5. CALLS FOR TENDERS .................................................................................................................................... 29 

5.1 Medical devices - Information campaign contracts ............................................................................ 29 

5.2 Investing for a healthy and inclusive EU ............................................................................................ 30 

6. HIGHLIGHTS OF CO-FUNDED ‘CROSS-CUTTING’ AND ‘OTHER’ ACTIONS ...................................... 32 

6.1 Dissemination activities carried out in 2019 ....................................................................................... 32 

6.2 Other actions ....................................................................................................................................... 33 

1 

 
 
6.2.1 Morbidity statistics ................................................................................................................................. 34 

6.2.2 Consistency between EHIS and EU-SILC Module on Health 2022 ...................................................... 35 

6.3 Final evaluation of the third health programme .................................................................................. 36 

7. IMPLEMENTATION OF ANNUAL WORK PROGRAMME 2019 ................................................................ 37 

7.1 Calls for proposals .............................................................................................................................. 37 

7.1.1 Joint Actions .......................................................................................................................................... 37 

7.1.2 Project grants ......................................................................................................................................... 39 

7.1.3 Project grants - Rare disease registries for the European Reference Networks ..................................... 40 

7.1.4 Grants for stakeholder projects to implement the EU guidelines on prudent use of antimicrobials 
in human health ............................................................................................................................................... 43 

7.1.5 Operating grants ..................................................................................................................................... 44 

7.1.6 Direct grant agreements and Presidency conferences ............................................................................ 47 

7.1.7 Other direct award of grants ................................................................................................................... 49 

7.2 Beneficiaries ....................................................................................................................................... 50 

7.3 Experts evaluators ............................................................................................................................... 51 

7.4 PRIZES – EU Health award for NGOS .............................................................................................. 52 

7.5 Procurements (service contracts) ........................................................................................................ 53 

7.6 Other actions ....................................................................................................................................... 77 

8. DETAILED OVERVIEW OF THE REPORTING YEAR 2019 ....................................................................... 82 

8.1 Funding per thematic priority and financial instrument ...................................................................... 82 

2 

 
 
 
 
 
Introduction 

This staff working  document (SWD)  accompanies the report on the implementation  of the third 

health programme (‘the programme’) in 2019.  

While  the  report  provides  an  overview  of  all  the  actions  funded  under  the  2019  annual  work 

programme (2019 AWP), this SWD presents the key results achieved in 2019 of actions that were 

co-funded  under  the  programme  in  previous  years  through  grants  and  service  contracts.  It 

provides  details  on  how  these  actions  contributed  to  the  programme’s  four  objectives,  and  how 

their results were taken up at national or EU level. 

This  SWD  also  provides  comprehensive  figures  and  statistics  on  the  programme’s  2019 

operational  budget,  including  a  list  of  all  co-funded  initiatives  and  contracts  by  programme 

objective, type of action and type of beneficiary organisation. 

More  information  about  these  actions  and  their  results  is  available  in  the  health  programme 

database managed by the Consumers, Health, Agriculture and Food Executive Agency (Chafea)1. 

1 The database covers actions co-funded under the Health Programmes from 2003-2020. 

3 

 
 
 
 
                                                      
 
1. JOINT ACTIONS 
Objective 2: Protect citizens from serious cross-border health threats 

1.1  Efficient response  to highly dangerous and emerging  pathogens at EU level 
(EMERGE) 
More information is available on the joint action website2 and in Chafea database3.  

Background information 

EMERGE  aimed  to  ensure  that  serious  emergent  and  re-emergent  cross-border  events  are 

responded  to  efficiently  by  strengthening  the  existing  EU  network  of  Bio-safety  level  3  and  4 

laboratories that already work to identify dangerous bacterial and viral human pathogens.  

It comprised a European network of about 40 diagnostic laboratories focused on different groups 

of bacteria and viruses of special concern, and involved 33 associated partners from 25 European 

countries.  

The total EU contribution amounted to EUR 3 499 873 for 46 months. 

Brief description of activities 

EMERGE  helped  establish  an  integrated  European  laboratory  network  and  strategy  to  protect 

Europeans against exposure to a number of globally-recognised high threat bacteria and viruses. 

Specific results  

EMERGE is having a positive long-term  effect  on the performance of diagnostic laboratories in 

identifying  highly  pathogenic  agents.  The  external  quality  assurance  exercises  (EQAEs)  and 

training helped to improve partner laboratories’ potential to respond during outbreaks. The EQAE 

certificates were used by partner laboratories for accreditation purposes. Interoperability between 

the partner laboratories and other institutions is already ensured when it comes to the diagnostics 

of  highly  pathogenic  bacteria  and  viruses,  as  demonstrated  by  the  coordinated  response  to  real 

outbreaks, such as Ebola in 2014-2015 and the Plague4. 

Its main results included: 

2 https://www.emerge.rki.eu  
3 https://webgate.ec.europa.eu/chafea_pdb/health/projects/677066/summary  
4 Microsoft Word - EMERGE-Plague-Recom_v7.docx (rki.eu)  

4 

 
 
 
                                                      
  Protocols  and  guidelines  on  outbreak  management,  and  recommendations  on  diagnostic 

approaches, by relevant networks and agencies, including the European Centre for Disease 

Prevention  and  Control  (ECDC),  that  continuously  assess  emerging  and  re-emerging 

infectious pathogens with the potential to cause cross-border outbreaks. 

 

Increased  diagnostic  capabilities  for  high  threat  pathogens  and  best  diagnostic  practices 

during outbreaks, especially in support of Member States without the required laboratory 

capacities/capabilities. 

  Assessment of the status quo and recommendations to improve laboratories’ capability and 

quality  to  diagnose  highly  pathogenic  viral  and  bacterial  agents,  as  well  as  pathogens  in 

‘unknown’  samples  in  an  inter-laboratory  approach  by  EQAEs,  and  establishment  of 

quality  assurances  of  diagnostics  in  cross-border  infectious  outbreaks  (with  reference 

material provided for both). 

  Five  EQAEs  were  carried  out  (two  viral,  two  bacterial  and  one  ‘unknown’)  and 

discussions were held  on  diagnostic  gaps and ways  to  address  them.  Partner laboratories 

improved or developed new standard operating procedures based on the EQAE results. An 

additional  ad  hoc  EQAE  was  performed  during  the  outbreak  response  mode  (ORM) 

simulation exercise. 

  A simulation exercise ‘Salutem’ was organised to rehearse practical laboratory testing and 

the decision-making processes of the EMERGE Steering Committee at different stages of 

an outbreak of highly infectious pathogens in several European countries5. 

The network of laboratories specialised in diagnosing highly infectious pathogens and/or viruses 

will continue to be supported through the SHARP (Strengthened International Health Regulations 

and Preparedness in EU6) joint action. SHARP’s aim is to strengthen member’s existing capacities 

and  support  improvements  in  international  health  regulation  (IHR)  capability  gaps.  SHARP 

partners  work  closely  with  diagnostic  laboratories  on  preparedness  and  IHR  implementation 

capacities.  

Objective 3 Contributing to innovative, efficient and sustainable health systems  

5https://www.emerge.rki.eu/Emerge/EN/Content/Topics/Publication/Exercise-Salutem-Public-
Report.pdf?__blob=publicationFile 
6 https://www.sharpja.eu/about-us/ 

5 

 
 
 
 
                                                      
1.2 Joint Action on Market Surveillance of Medical devices (JAMS) 
More information is available on the joint action website7 and in Chafea database8.  

Background information 

JAMS aimed to strengthen the market surveillance system for medical devices by improving the 

coordination  of  activities  between  EU  countries,  and  ensuring  good  communication  and 

cooperation.  

JAMS was built around two key principles:  

•  Share  and  develop  best  practice,  training,  knowledge,  and  resources  to  increase  public  health 

protection in the medical devices sector. 

• Improve coordination and help to develop skills and capacity in the market surveillance network. 

The  overarching  aim  of  the  joint  action  was  to  ensure  consistently  high  health  and  safety 

protection for EU patients using medical devices. 

The total EU contribution amounted to EUR 849 488.    

Brief description of activities  

JAMS  contributed  to  Objective  3  of  the  health  programme  by  developing  tools  to  enable  joint 

inspections  of  manufacturers,  and  developing  resources  and  platforms  to  improve  clinical 

processes  and  market  surveillance  coordination  between  Member  States.  It  helped  lower-

resourced  Member  States,  in  particular,  develop  skills  and  capacity  in  the  market  surveillance 

network.  It  ensured  a  consistent  and  proportionate  approach  across  all  Member  States  to 

manufacturer inspections, clinical process and resource development. 

Specific results  

7 www.camd-europe.eu › 
 Market surveillance of medical devices (JAMS) - CAMD : CAMD (camd-europe.eu) www.camd-europe.eu › 
8 https://webgate.ec.europa.eu/chafea_pdb/health/projects/723964/summary  

6 

 
 
 
 
 
                                                      
The first three work packages (WPs) involved coordination, dissemination and evaluation, WP 4 

focused  on  joint  inspections  of  manufacturers  and  WP  5  on  clinical  process  and  resources 

development. 

WP  4  resulted  in  methods,  tools  and  guidance  for  a  consistent  and  proactive  approach  to 

manufacturers’  inspections  and  inspectors’  training  courses  by  national  competent  authorities 

(CAs).  It  further  established  specific  inspection  scopes  and  objectives  to  complement  those 

conducted by conformity assessment bodies.  

WP 5 resulted in a communication platform for national CAs to discuss –confidentially and in real 

time  -  market  surveillance  issues  affecting  several  of  them.  JAMS  also  developed  a  training 

strategy  to  give  practical  guidance  on  assessing  and  reviewing  of  clinical  data.  Finally,  this 

cooperation helped identify the priorities for developing common specifications. 

The  JAMS  Stakeholder  Conference,  held  in  December  20199,  gathered  representatives  from  24 

competent  authorities  for  medical  devices,  the  Commission  (DG  GROW,  DG  SANTE  and 

Chafea) and 15 interested stakeholders to share and discuss the results and the next steps.  

JAMS helped improve the level of scrutiny that CAs have on medical devices in the EU. Indeed, 

the regulatory systems  governing the  medical  devices industry  are now better equipped and  can 

efficiently  and  effectively  maintain  oversight  of  the  industry.  This  positively  affects  both  the 

safety  of  medical  devices  in  Europe,  and  the  level  of  confidence  that  patients,  consumers  and 

healthcare professionals have in such devices.  

Objective 4: Facilitating access to better and safer healthcare for Union citizens  

1.3  Vigilance  and  inspection  for  the  safety  of  transfusion  assisted  reproduction 
and transplantation (VISTART) 
More information is available on the joint action website10 and in Chafea database11. 

Background information 

9 https://www.camd-europe.eu/events/jams-stakeholder-conference-held-in-brussels-on-dec-12th-2019/ 

10 https://vistart-ja.eu//  
11 https://webgate.ec.europa.eu/chafea_pdb/health/projects/676969/summary  

7 

 
 
 
 
 
 
 
                                                      
Seven EU  directives  on  blood,  tissues and  cells (BTC), adopted between  2002 and 2006,  put  in 

place  a  quality  and  safety  (Q&S)  framework  for  the  donation,  testing,  collection/recovery, 

processing, storage and distribution of these substances of human origin.  

Around a decade after the adoption of the BTC directives, it was apparent that the Q&S principles 

to protect recipient patients were largely common across these types of donation and that greater 

consistency and significant efficiency improvements could be achieved by harmonising some of 

the guidance and tools in use at EU level.  

VISTART  evaluated  some  key  EU  tools  and  proposed  to  consolidate  them  -  particularly  the 

inspection guide, guidance on preparation process authorisation and import and export, inspection 

training, and guidance for annual vigilance reporting and for issuing rapid alerts. It aimed to help 

EU  Member  States  develop  and  strengthen  their  monitoring  and  control  capacity  in  the  area  of 

blood transfusion and tissue and cell transplantation.  

The joint action involved 14 partners from 14 European countries.  

The total EU contribution amounted to EUR 2 328 664. 

Brief description of activities  

VISTART aimed to help harmonise the inspection, authorisation and vigilance systems for BTC, 

including reproductive cells, and to improve collaboration between Member States by increasing 

mutual  confidence  in  their  inspection  and  vigilance  systems.  It  also  aimed  to  increase  the 

consistency and efficiency of competent authorities’ regulatory activities by introducing EU-level 

tools  applicable  across  BTC  used  in  transfusion,  transplantation  and  assisted  reproduction. 

VISTART’s  technical  work  packages  covered:  vigilance  (WP4  and  WP5A),  new  processes  for 

tissues  and  cells  (WP5B),  the  Single  European  Coding  System  (SEC)  (WP10)  and  inspections 

(WP6, 7, 8, 9). 

Specific results 

WP4  focused  on  ‘Horizon  scanning  for  identifying  new  risks  related  with  the  donation  of 

substances  of  human  origin  that  may  be  of  relevance  to  patient  safety  or  BTC  availability’.  It 

examined  the  risk  response  procedures  in  place  at  national  and  international  levels  and  the 

notification tools used by Member States, assessed their strengths and weaknesses, and developed 

8 

 
 
 
guidelines on horizon scanning activities to identify new risks from pathogens. It also formulated 

recommendations on appropriate preventive measures to be developed and communicated at EU 

and national level. 

WP 5 - Part A helped increase the involvement of EU competent authorities in the WHO didactic 

tool  developed  and  managed  by  the  Italian  National  Transplant  Centre  (CNT):  the  Notify 

Library12.  The  library  is  an  open  access  searchable  database  of  reliably  documented  adverse 

occurrences arising from the donation, preparation or clinical application of substances of human 

origin.  It  aims  to  share  this  information  as  widely  as  possible  to  improve  processes  to  better 

protect  donors  and  patients.  This  collaboration  resulted  in  competent  authorities  transferring 

information  from  their  annual  serious  adverse  reactions  and  events  (SARE)  reports  into  the 

Library’s  database,  with  the  help  of  practical  guidelines  on  ‘How  to  select  and  prepare  SARE 

cases of didactic value for insertion in the Notify Library - a user guide for competent authorities’. 

WP10  helped  EU  tissue  establishments  (TEs)  and  professionals  working  on  the  provision  of 

tissues  and  cells  for  human  application,  comply  with  Commission  Directive  (EU)  2015/  565  on 

the Single European Code (SEC). It provided them with an overview of the legal background and 

the  available  tools  for  implementing  the  SEC  requirements  in  their  country.  EU  competent 

authorities now have full access to the EU coding platform for tissues and cells13 and can manage 

information on their TEs. An e-learning course with locally-adjustable training material was also 

made available to all competent authorities and may be uploaded onto an e-learning platform in 

the near future. 

12 https://www.notifylibrary.org  
13 https://webgate.ec.europa.eu/eucoding  

9 

 
 
 
                                                      
2. PROJECTS  
Objective 1 – Promote health, prevent diseases and foster supportive environments 

for health lifestyles  

2.1  Raising  awareness  and  action-research  on  heavy  episodic  drinking  among 
low-income youth and young adults in Southern Europe (AllCool)  
More information is available on the project website14 and in Chafea database15.  

Background information 

The AllCool project was launched in May 2016 in Portugal, Spain and Italy. It aimed to contribute 

to a better understanding of heavy episodic drinking in order to inform comprehensive measures 

and policies to address it. Although heavy episodic drinking occurs in several societal groups, it is 

the main drinking pattern found in youth and young adults. This worrying phenomenon is growing 

among adolescents and young adults, mainly in low-income countries and in western societies.  

The EU contribution amounted to EUR 236 843.80.  

Brief description of activities  

This  project  aimed  to  contribute  to  the  reduction  of  alcohol-related  harm  among  low-income 

youth  and  unemployed  young  graduates.  Given  the  complexity  of  this  phenomenon,  one  of  the 

major  concerns  of  the  AllCool  project  was  the  need  to  closely  link  research,  intervention  and 

policies. It therefore encompassed four main methodologies: (i) action-research, (ii) networking, 

(iii) informal education through training and (iv) informal education through consultative forums 

and harm reduction interventions. 

Specific results  

Key project results included:  

 

Increased  professional  skills  and  confidence  in  managing  and  working  in  European 

partnership. 

14 https://apdes.pt/en/home-en/  
15 https://webgate.ec.europa.eu/chafea_pdb/health/projects/710063/summary  

10 

 
 
 
                                                      
  Design and implementation of innovative local measures adapted to the specific challenges 

faced  by  each  city  in  the  consortium.  This  was  achieved  by  closely  linking  research, 

community intervention, consultative forums and harm reduction measures.  

 

Increased professional skills in linking research with implementation and advocacy thanks 

to scientific presentations of project results, close links and intensive communication with 

consultative forums stakeholders and communication on the project’s results on websites 

and social media and in newsletters. 

2.2 Operational refugee and migrant maternal approach (ORAMMA) 
More information is available on the project website16 and in Chafea database17.  

Background information  

ORAMMA  aimed  to  improve  the  outcomes  of  pregnancies  in  migrants,  asylum  seekers  and 

refugees,  by  training  health  and  social  care  providers  on  cultural  competences  and  providing 

support by other migrant women, called ‘maternity peer supporters’18.  

It developed, piloted and evaluated by comparative analysis with an integrated and cost-effective 

approach  as  regards  safe  motherhood  provision  for  migrant,  asylum  seeking  and  other  refugee 

women, taking into consideration: 

• best practices 

• the special risks and characteristics of the target group and 

• the transferability of the model in different healthcare systems across the EU: from camp sites in 

Greece,  to  the  National  Health  Service  in  the  United  Kingdom,  and  the  community-based 

midwifery model in the Netherlands. 

ORAMMA  brought  together  eight  partners  from  four  Member  States  (Greece,  the  Netherlands, 

Belgium and the United Kingdom).  

The EU contribution amounted to EUR 477 014.37.  

16 http://oramma.eu/  
17 https://webgate.ec.europa.eu/chafea_pdb/health/projects/738148/summary  
18  A  maternity  peer  supporter  is  a  woman  with  a  migrant  background  who  acts  as  a  cultural  bridge  between  the 
pregnant migrant and the midwife. 

11 

 
 
 
 
 
                                                      
 
Brief description of activities   

The ORAMMA project developed an integrated mother- and woman-centred, culturally-sensitive 

and evidence-based approach to perinatal healthcare for migrant and refugee women. The method 

for this was:  

(a) desk research to collect updated information on national practices for the perinatal healthcare 

of migrant and refugee women,  

(b) a qualitative survey on midwives thought the network of the European Midwives Association,  

(c) a literature review of scientific papers and reports from major health organisation (such as the 

WHO) and medical journals on perinatal healthcare of migrant and refugee women (special risks, 

best practices, case studies, implementing tools, social issues etc.) and,  

(d) development of the main project deliverables, as shown below.  

Specific results 

Key project results included:  

  A  practice  guide  for  perinatal  healthcare  for  migrant,  asylum  seeking  and  refugee 

women19:  A  practice  guide  for  healthcare  professionals  with  recommendations  and 

guidelines on the specific needs of migrant/refugee mothers, evidence and good practices 

for the antenatal, intrapartum and postnatal care of new migrant, asylum seeker or refugee 

women.   

  A training handbook for maternity peer supporters20 with educational material relevant for 

their training/capacity-building activities. 

  A  training  handbook  for  health  and  social  care  providers21  with  comprehensive  training 

material on perinatal healthcare for migrant and refugee women. 

  An e-learning course22 to give health professionals the necessary knowledge and skills to 

provide  migrant  and  refugee  maternal  care.  The  course  includes  knowledge  tests,  video 

lectures and presentation material. 

19 http://oramma.eu/wp-content/uploads/2018/12/ORAMMA-D4.1-Practice-Guide_REVIEWED.pdf 
20 http://oramma.eu/wp-content/uploads/2019/07/ORAMMA_MPSs_training-handbook-D5.1.pdf  
21 http://oramma.eu/wp-content/uploads/2019/07/ORAMMA_HCPs_training-handbook-D5.2.pdf  
22 oramma.eu/e-course/ 

12 

 
 
 
 
                                                      
Objective 3 Contributing to innovative, efficient and sustainable health systems  

2.3 FRAILTOOLS23: a comprehensive validation of tools to screen and diagnose 
frailty  in  different  clinical  and  social  settings  to  provide  instruments  for 
integrated care in older adults 

More information is available on the project website24 and in Chafea database25.  

Background information 

Strong evidence points to frailty being a useful indicator to predict certain undesired outcomes in 

older  populations.  Several  studies  have  shown  its  usefulness  for  improving  prognoses  and 

predicting various  risks  (hospitalisation, surgical  and non-surgical  complications,  length  of stay, 

death,  incident  disability,  etc.)  in  emergency  departments,  cardiac  surgery,  surgical  patients  and 

in-patients with cardiovascular disease. These studies have focused on assessing population risk, 

while the validation process for these instruments as diagnostic or screening tools has been largely 

neglected.  

The  FRAILTOOLS  consortium  involved  six  partners  from  Spain,  the  UK,  Italy,  France  and 

Poland, as well as some highly relevant and committed collaborating stakeholders. 

The EU contribution amounted to EUR 1 124 463.  

Brief description of the activities 

The partners assessed the usefulness of a selection of instruments as screening and diagnosis tools 

to detect frailty (through clinically-sound algorithms) in both clinical (hospital and primary care) 

and social (nursing homes) settings. The target group was older adults at risk of frailty (pre-frail) 

and those that are already frail and at risk of developing a disability. Around 40-50% of people 

over 65 and 60-70% of people over 75 fall into these categories.  

23  The  frailty  syndrome  is  a  physiological  condition  characterised  by  increased  vulnerability  and  sensitivity  to 
physical,  psychological  and  social  stressors  affecting  older  people  all  over  the  world.  It  is  associated  with  genetic 
factors,  the  ageing  process,  multimorbidity,  eating  disorders  and  lack  of  physical  activity.  It  affects  1  in  10  people 
over  65  and  1  in  3  people  over  90.  Frailty  is  also  more  common  in  long-term  care.  Some  studies  reported  that  it 
affects up to 68% of nursing home residents.  
24 http://www.frailtools.eu/  
25 https://webgate.ec.europa.eu/chafea_pdb/health/projects/662887/summary  

13 

 
 
 
 
 
 
                                                      
FRAILTOOLS  contributed  to  the  Commission’s  initiative  on  frailty,  integrated  care  and  multi-

chronic conditions by: 

  applying  coordinated  and  innovative  preventive  measures,  developing  and  implementing 

screening and early diagnostic programmes for frailty, optimising functional capacity and 

developing guidelines on managing frailty; 

 

improving 

healthcare 

systems, 

implementing 

health 

promotion 

strategies,  

facilitating  the  exchange  of  good  clinical  practice,  expanding  knowledge  networks,  and 

driving healthcare innovation at European level.  

Specific results  

The  partners  evaluated  eight  frailty  assessment  instruments:  (i)  Frailty  Phenotype;  (ii)  FRAIL 

Scale;  (iii)  Rockwood  35-item;  (iv)  CSHA  Clinical  Frailty  Scale;  (v)  SHARE  FI;  (vi)  The 

Gérontopôle Frailty Screening Tool;  (vii) and (viii) Shorten version of the Frailty Trait Scale (3 

and 5 items).  

Frailty was detected in 42.93% of patients. Its prevalence varied depending on the setting and the 

tool  assessed.  The  tools  showed  that  the  highest  rate  of  frailty  was  in  nursing  homes  (93.5% 

according  to  Rockwood  35-item),  followed  by  geriatric  wards  (74.6%  reported  by  SHARE  FI). 

The lowest rate of frailty was in general practice (6.9% at stated in FTS3 Frailty Trait Scale (>15).  

In  general,  the  degree  of  concordance  was  found  to  be  low  between  the  instruments  evaluated, 

suggesting  that  they  are  probably  measuring  different  clinical  entities.  This  is  probably  why 

several subtypes of frailty syndrome exist. 

The results of the FRAILTOOLS study will make it possible to:  

 

Identify  the  best  instruments  to  assess (screen and/or diagnose) frail older adults in  each 

setting:  geriatric  wards  (in-patients),  geriatric  consultation  (outpatients);  primary  care; 

nursing homes.  

  Provide sequential algorithms to diagnose frailty by setting (geriatric outpatients; primary 

care;  nursing  homes)  and  between 

the  settings.  These  results  will  feed 

into 

recommendations  for  healthcare  authorities  on  incorporating  frailty  diagnosis  tools  into 

protocols for following up older patients. 

14 

 
 
 
 
2.4 Scaling integrated care in context (SCIROCCO)  
More information is available on the project website26 and in Chafea database27.  

Background information 

In 2012, under the European innovation partnership on active and healthy ageing (EIP on AHA), 

the Commission set up an action group on integrated care to increase healthy life years by scaling-

up innovative active and healthy ageing solutions. Scaling-up means extending the coverage of a 

certain health measure, usually by increasing the relevant financial and human resources.  

SCIROCCO  aimed  to  build  on  the  work  of  this  action  group  and  help  scale-up  integrated  care 

solutions  by  facilitating  effective  knowledge  transfer  and  exchange  of  good  practices  at  local, 

regional or country level, in full consideration of the local context in which a good practice was 

developed  and  the  conditions  for  its  transferability  to  different  settings.  A  key  notion  of  the 

‘Maturity Model’ developed in SCIROCCO is that of context and transferability.  

The EU contribution amounted to EUR 1 322 775.00.  

Brief description of activities  

The SCIROCCO project validated, tested and operationalised the Maturity Model in the form of 

an easy-to-use online self-assessment tool that focuses on helping  regions to  scale-up integrated 

care. 

SCIROCCO explored how European regions can: 

 

receive  practical  support  for  the  scaling-up  of  good  practices  that  promote  active  and 

healthy ageing and participation in the community;  

 

improve their capacity and readiness for adoption and scaling-up of integrated care;  

  develop a strong basis for successful twinning and coaching that will facilitate their shared 

learning, exchange of good practices and scaling-up of integrated care;  

 

improve informed decision-making on future actions and priorities for the improvement of 

local conditions enabling the adoption and scaling-up of integrated care. 

26 https://www.scirocco-project.eu/  
27 https://webgate.ec.europa.eu/chafea_pdb/health/projects/710033/summary  

15 

 
 
 
                                                      
Specific results 

SCIROCCO  developed  an  online  self-assessment  tool  for  integrated  care  based  on  the  Maturity 

Model developed by the action group on integrated care. The tool is user-friendly and available in 

English,  Czech,  Italian  and  Spanish.  The  partners  also  developed  videos  and  other  training 

material  to  support  the  use  of  the  tool.  The  tool  can  be  used  to:  (a)  assess  the  maturity 

requirements of good practices, and/or (b) assess the maturity/readiness of health and social care 

systems.  More  than  30  European  regions  are  currently  testing  the  SCIROCCO  Maturity  Model 

and stakeholder feedback is being gathered and analysed to inform its future potential use28. 

As a result, a follow-up project, ‘Personalised knowledge transfer and access to tailored evidence-

based assets on integrated care: SCIROCCO Exchange29’, was launched in 2019 and will run until 

the end of September 2021.  

Objective 4: Facilitating access to better and safer healthcare for Union Citizens  

2.5 Good practices for demonstrating safety and quality through recipient follow-
up [Euro-GTP II] 
More information is available on the project website30 and in Chafea database31.  

Background information  

Advances in basic science, technology and medicine continually create opportunities for new and 

improved tissue and cellular therapy/ products (TCTP). These may be completely new products, 

or improved methodologies for preparing existing TCTPs. While these advances aim to develop 

TCTPs that are safer, clinically more effective and meet the needs of clinicians and patients, there 

is always a risk that any change in the processing method can harm the recipient.   

Euro-GTP  II  aimed  to  define  the  threshold  of  novelty  as  well  as  the  factors  to  consider  when 

determining 

the 

scope 

and 

depth 

of 

the 

clinical 

follow-up 

studies 

needed. 

It  aimed  to  establish  a  tissue  and  cells  (T&C)  database  of  products,  preparation  procedures  and 

28 https://www.scirocco-project.eu/scirocco-tool/  
29 https://www.sciroccoexchange.com/ 
30 http://www.goodtissuepractices.eu/  
31 https://webgate.ec.europa.eu/chafea_pdb/health/projects/709567/summary  

16 

 
 
 
 
                                                      
clinical applications, with information on their authorisation and implementation status. This was 

intended  as  a  starting  point  for  determining  the  ‘novelty’  of  processes/therapies  by  Tissues 

Establishments (TEs) and the Organisation Responsible for Human Application (ORHA), and for 

allowing  the  use  of  established  processes/therapies  by  any  centre  that  strictly  follows  the  same 

procedure/clinical procedure/indication. The project also aimed to define a ‘Good tissues and cells 

practices (GTP) management model’ to enable future standards harmonisation and promotion, and 

enable European accreditation and training programmes to be set up for TE. 

The project involved 14 partners from 11 Member States, and 12 collaborative partners. 

The EU contribution amounted to EUR 1 032 024.00.  

Brief description of activities  

Euro-GTP II’s four core work packages determined: 

-  methodologies  for  assessing  the  risk  associated  with  novel  tissues/cells  and  for  assessing  the 

extent  of  the  studies  needed  to  provide  quality,  safety  and  efficacy  data  for  the  tissues/cells 

applications; 

-  the  follow-up  programmes  to  assure  safety  and  efficacy  and  to  confirm  the  validation  of  the 

processing methods. 

Specific results  

The  project  developed  good  practices,  principles  and  reference  tools  for  TCTPs  and  on  how  to 

conduct adequate clinical evaluations. It proposed methodologies to be applied systematically and 

consistently to ensure standard practices and recognition among the stakeholders.  

Euro-GTP II proposed a systematic approach to:  

  evaluate  risks  resulting  from  all  aspects  of  T&C  supply  chain  (from  donor  selection  to 

clinical application) of the final product;  

  design appropriate studies proportionate to the level of residual/unknown risk in order to 

confirm that the TCTP is safe and effective.  

Its three key results were:  

  a systematic, risk-based mechanism and interactive assessment tool (IAT);  

17 

 
 
  a  database  of  tissues/cells  products,  preparation  processes,  applications  and  therapies  - 

structure  defined  to  publish  data  related  to  the  products  and  therapies  available,  and 

support end users in the evaluation of TCTPs for safe and efficacious use;  

  a GTP management model which assures the continuity and sustainability of the outcomes 

of  the  Euro  GTP  II  Project,  and  the  future  update,  promotion  and  harmonisation  of 

standards32.  

While  all  the  tools  were  developed  to  assist  professionals  in  their  daily  activities,  an  effort  was 

done  to  align  the  guidance  and  tools  with  regulatory  principles,  legislation  and  good  practices. 

The  tools  are  also  available  to  national  competent  authorities  and  may  therefore  facilitate  their 

evaluation and the authorisation procedures.  

3. OPERATING GRANTS 
Fifteen  (15)  non-governmental  organisations  (NGOs)  that  signed  a  framework  partnership 

agreement (FPA) in 201733 were invited to submit their proposals for a specific grant agreement 

(SGA) to cover their 2019 recurrent operational expenses.  

As shown in Table 1 below, the FPAs and their SGAs contribute to three 3rd health programme 

objectives,  with  10  NGOs  addressing  Objective  1  (Promote  health,  prevent  diseases  and  foster 

supportive  environments  for  healthy  lifestyles,  taking  into  account  the  'health  in  all  policies' 

principle’)  one  contributing  to  Objective  3  (Contribute  to  innovative,  efficient  and  sustainable 

health  systems)  and  three  to  Objective  4  (Facilitate  access  to  better  and  safer  healthcare  for 

Union citizens). 

Table 1: List of applicant organisations awarded an FPA 2017-2021 and subsequent SGAs  

Acronym 

Organisations 

EPHA  
EUPHA 
SFP  
ENSP  
SHE 
Network 

EPHA multiannual work programme 
Application for an operating grant EUPHA 
SFP Coalition's multiannual work plan  
ENSP - The Network - United for a tobacco-free Europe 
SHE Schools for health in Europe Network 

Thematic 
priority 

1.1 
1.1 
1.1 
1.1 
1.1 

32 http://www.goodtissuepractices.eu/index.php/project-outcomes  
33 Of the 16 applications received, 15 were evaluated and one was withdrawn as it was a duplicate. Only one of them 
was put on the reserve list due to the unavailability of funds.  

18 

 
 
                                                      
AE 
ECL  

HAI 

Stronger together 

AAE 
C- EHRN  Correlation Network on harm reduction and social inclusion 
TBEC 

Strengthening the capacity and capability of civil society to drive the 
TB response in Europe 
Alzheimer Europe  
European Cancer Leagues collaborating for impact in cancer control 

A plan for action: Ensuring equitable, affordable and responsibly used 
medicines in the European Union 

Eurordis   EURORDIS - the voice of rare disease patients in Europe 
THALIA  Thalassaemia in action 
SAVDON  High-quality blood stem cells products available for all patients in 

need, and to protect the rights and welfare of volunteer stem cell 
donors 

1.3 
1.3 
1.3 

1.4 
1.4 

3.6 

4.2 
4.2 
4.5 

Throughout 2019, in line with their SGAs, the organisations achieved their objectives, produced 

valuable work  for their stakeholders and supported  Commission health policy initiatives in their 

areas of activity.  

The  work  and  outcomes  of  three  of  these  organisations  (EPHA,  HAI  and  EURORDIS  active 

under thematic priority 1.1, 3.6 and 4.2 respectively) is described below. 

3.1 EUROPEAN PUBLIC HEALTH ALLIANCE 

More information about the work of the European Public Health Alliance (EPHA) is available on 

the organisation’s website34 and in Chafea database35.   

Background information  

EPHA works in eight thematic priority areas: prevention of chronic  non-communicable diseases 

(NCDs),  access  to  affordable  medicines,  antimicrobial  resistance,  digital  health,  healthy  trade 

policy, improving access to healthcare for disadvantaged groups, financing for public health, and 

capacity building.  

It  focuses  strongly  on  ensuring  the  transfer  of  knowledge  between  the  EU  and  national  level  to 

support the priorities of the 3rd health programme and to emphasise the added value of EU health 

policies. 

34 https://epha.org/  
35 https://webgate.ec.europa.eu/chafea_pdb/health/projects/837500/summary  

19 

 
 
 
                                                      
Brief description of activities 

EPHA carries out different types of activities in each of its eight priority areas to effectively fulfil 

its role as Europe’s largest public health umbrella network. These activities are fundamental for 

implementing  its  five-year  strategic  plan  and  achieving  the  main  aims  of  the  SGA  and  the 

milestones and deliverables it sets out.  

EPHA’s methods include gathering,  analysing and disseminating evidence and intelligence (e.g. 

via articles, reports, surveys, policymaker meetings, etc.), consensus development (among EPHA 

members  and  with  partner  organisations),  advocacy  and  representation,  event  organisation,  and 

building  capacity  of  public  health  organisations,  with  a  focus  on  less  affluent  Member  States.  

EPHA  closely  monitored  evolving  policy  developments  related  to  public  health  at  EU  and 

national levels, as well as changes to the political, economic, social and cultural environment that 

influence  public  health  and/or  provide  opportunities  or  challenges.  EPHA’s  activities  targeted  a 

diverse  audience  from  high-level  EU  and  national  decision-makers  to  health  professionals  and 

patients, underserved groups and the public. 

EPHA  representatives  spoke  at  more  than  70  events  and,  EPHA  provided  input  for  7  public 

consultations, participated in 9 expert groups or committees and in 5 steering groups. EPHA also 

remained an active user of the European Health Policy Platform, leading its Stakeholder Network 

on  antimicrobial  resistance  (AMR)  and  providing  input  for  the  ‘Nobody  left  outside’  joint 

statement that contains concrete policy tasks for tackling health inequalities in Europe. 

As  in  the  previous  year,  EPHA  took  care  to  identify  and  disseminate  best  practices  in  all  of  its 

work  streams  to  emphasise  the  EU  added-value  of  health  action  and  support  the  third  health 

programme.  

Specific results 

Through the 2019 SGA, EPHA provided its target groups, including policymakers, civil society, 

and  ordinary  people  with  new  evidence-based  knowledge  and  recommendations  for  tangible 

support  to  the  third  health  programme’s  objective  on  strong,  resilient  and  sustainable  health 

systems. For example, its work on preventing non-communicable diseases and its focus on healthy 

and  sustainable  food  and  drink  environments,  with  a  new  mapping  tool  for  healthy  living 

environments,  enabled  an  active  exchange  of  information  and  dialogue.  In  the  area  of  trade, 

20 

 
 
EPHA drafted a ‘Model  Health Chapter’  (together with members the European Heart Network), 

which EU policymakers can consider as a reference tool for future trade negotiations.  

EPHA also submitted papers on artificial intelligence/big data and digitalisation in public health. 

It also raised awareness  about public health challenges among healthcare professionals, students 

and  patients.  Its  messages  on  antimicrobial  resistance  (AMR),  for  example,  aimed  to  encourage 

behaviour  change  without  losing  sight  of  the  need  to  strengthen  political  leadership  and  ensure 

adequate  funding  for  AMR  strategies  and  research.  EPHA  continued  to  provide  a  civil  society 

perspective of public health developments and building up health literacy, e.g. of non-traditional 

users of digital health and marginalised Roma communities via its network of national partners.  

3.2 Health Action International (HAI)  

More  information  about  the  work  of  HAI  is  available  on  the  organisation’s  website36  and  in 

Chafea database37. 

Background information  

HAI aims to respond to shortcomings in European medicines policy and regulation. Its work plan 

aligns  with  the  third  health  programme’s  objectives  and  its  own  three  goals:  (1)  access  to 

affordable medicines; (2) medicines safety, added therapeutic value and responsible use; and (3) 

democratisation of medicines policy. Through the SGA, HAI continued to implement initiatives to 

promote  responsible  use  of  medicines,  including  antibiotics,  by  healthcare  professionals.  As  a 

member  of  the  Health  Technology  Assessment  (HTA)  Network  Stakeholders  Pool,  HAI 

contributes  to  the  work  programme  of  the  network  and  advocates  for  strengthened  EU 

collaboration  on  HTA.  As  a  member  of  the  European  Medicines  Agency  (EMA)  Patients’  and 

Consumers’  Working  Party  (PCWP),  HAI  brings  an  independent  consumers’  voice  to  EMA’s 

discussions and public consultations. 

Brief description of activities  

HAI  used  a  variety  of  methods  to  suit  the  objective  and  target  group,  and  worked  alone  or  in 

cooperation with members and partner organisations depending on the activity. In engaging with 

36 https://haiweb.org/  
37 https://webgate.ec.europa.eu/chafea_pdb/health/projects/836477/summary  

21 

 
 
                                                      
policymakers,  for  example,  HAI  made  use  of  policy  papers,  public  consultation  responses,  and 

one-on-one meetings and organised public conferences, workshops and awareness campaigns (e.g. 

Our Medicines, Our Right). HAI also continued to engage in civil society coalitions and strategic 

partnerships in order to maximise the impact their work.   

Specific results 

As part of the ‘Our Medicines, Our Right’ campaign, HAI organised two breakfast meetings and 

two  events,  and  developed  11  campaign  materials  and  two  policy  briefs  targeting  Dutch 

policymakers.  To  increase  support  from  regulators  and  policy  makers  for  higher  standards  on 

medicines  marketing  authorisation,  HAI  produced  various  materials  and  published  them  in  its 

online database on ‘Risk biases in clinical trials for cancer medicines in the EU’, prepared a policy 

brief  with  recommendations  to  improve  marketing  authorisation  procedures  and  organised  eight 

meetings with civil society organisations (CSOs) and/or policymakers.  

The database now has over 1000 users. Academics and decision-makers can either use the data for 

their own research/work and/or add to it by sharing their own findings. The policy brief ‘Clinical 

Trials  in  the  European  Union:  A  Roadmap  to  Greater  Transparency’,  written  together  with 

TranspariMED, called on EMA to take a more proactive role in enforcing transparent practices.  

To fill the educational gap for students at targeted EU universities, it developed tools to help them 

critically  assess  pharmaceutical  promotion  and  ensure  rational  prescribing,  including  two 

webinars, a rebranded ‘Fact or Fiction’ manual, quizzes and an explainer video.  

3.3 EURORDIS 
More information about the work of EURORDIS is available on the organisation’s website38 and 

in Chafea database39. 

Background  

EURORDIS  is  a  non-governmental,  patient-driven  alliance  of  patient  organisations  and 

individuals  who  are  dedicated  to  improving  the  quality  of  life  of  everyone  living  with  a  rare 

38 https://www.eurordis.org/  
39 https://webgate.ec.europa.eu/chafea_pdb/health/projects/838112/summary  

22 

 
 
                                                      
disease in Europe40. It advocates for people living with rare diseases, supports patient engagement 

at EMA, as well as in HTA and ERN activities, and provides patients with training, information 

on  all  aspects  of  their  condition,  and  networking  opportunities.  Its  calendar  includes  the 

EURORDIS  Open  Academy,  the  EURORDIS  Membership  Meeting,  Rare  Disease  Day  and  the 

European Conference for Rare Diseases. It also runs a comprehensive website, publishes regular 

newsletters, organises webinars and is active on social media. 

Brief description of activities  

EURORDIS’ 2019 work plan was organised along the following main strategic objectives:  

  To consolidate the rare disease patient’s community and strengthen the rare disease patient 

voice;  

  To  actively  engage  rare  disease  patient  representatives  to  contribute  to  the  adoption, 

effective implementation and monitoring of relevant legislation/strategies;  

  To build capacities and empower rare disease patients advocates, members and volunteers;  

  To sustain human, financial and organisational resources. 

To achieve these objectives EURORDIS organised meetings and training sessions; produced and 

published  documents,  reports  and  information  material;  and  reached  out  to  the  community  and 

stakeholders through webinars, conference calls and face-to-face meetings. 

Specific results 

The 2019 edition of Rare Disease Day involved over 100 participating countries – the most ever. 

In 2019, EURORDIS also updated its ‘Show Your Rare’ campaign videos with three new patient 

testimonials, which it produced with three national alliance partners. The videos had over 138 000 

views on social media and YouTube and were translated into 35 languages.  It also carried out a 

strategic review on the future of Rare Disease Day. 

Building on its 10-year experience in capacity-building programmes, EURORDIS developed and 

launched the EURORDIS Open Academy consolidating all of EURORDIS’ training activities. In 

40 Four patient groups active in different therapeutic fields founded EURORDIS in 1997: the Association Française 
contre  les  Myopathies  (AFM),  Vaincre  la  Mucoviscidose,  Ligue  nationale  contre  le  Cancer  (LNCC),  and  AIDES 
Fédération.  Today,  it  is  supported  by  its  members  and  by  the  Association  Française  contre  les  Myopathies,  AFM- 
Téléthon, the European Commission, corporate foundations and the health industry. 

23 

 
 
                                                      
2019,  EURORDIS  delivered  four  training  programmes  (involving  both  online  and  face-to-face 

training)  at  the  Open Academy  summer school  (on medicine research and development), winter 

school  (on scientific  innovation and  translational  research), as well as  the leadership school  and 

the digital school.  

The  summer  school  (11th  edition)  brought  together  34  participants  (patient  advocates  and 

researchers) from 15 countries and included a 4.5-day face-to-face training session in Barcelona, 

Spain. An online pre-training programme is available on the EURORDIS website for anyone who 

is  interested  to  follow  it.  The  total  number  of  summer  school  alumni  since  2008  stands  at  508. 

4. DIRECT GRANT WITH INTERNATIONAL ORGANISATIONS 

4.1 Country Health Profiles 2019 (OECD and European Observatory on Health 
Systems and Policies); Health at a Glance: Europe 2020 (OECD)  

Main objective 

The ‘State of Health in the EU’ report aims to make health system information, expertise and best 

practices  easily  accessible  to  policy  makers  and  all  other  shapers  of  health  policy.  The  latest 

evidence on health is gathered in a series of concise, digestible reports. The project is managed by 

the  European  Commission,  but  benefits  from  the  work  of  the OECD’s  Health  Division  and  of 

the European Observatory on Health Systems and Policies (Observatory), a partnership hosted by 

the World Health Organization (WHO).  

On  28  November  2019,  the  Commission  published  the  second  edition  of  the  biennial  country 

health profiles41 - an important step in the European Commission’s State of Health in the EU cycle. 

The country health profiles are released once every 2 years, alternating with the release of Health 

at  a  Glance:  Europe42,  which  is  developed  by  the  Commission  in  close  cooperation  with  the 

OECD’s Health Division.  

41 The Country Health Profiles can be found here: https://ec.europa.eu/health/state/country_profiles_en 
42 Health at a Glance: Europe 2020 can be found here: 
https://ec.europa.eu/health/sites/default/files/state/docs/2020_healthatglance_rep_en.pdf  

24 

 
 
 
 
                                                      
The  2020  edition  of  Health  at  a  Glance:  Europe  stems  from  the  grant  awarded  under  the  2019 

annual work plan. It is one of the outcomes of the State of Health in the EU cycle, a key action of 

the 3rd health programme.  

The  next  step  in  the  ‘State  of  Health  in  the  EU’  cycle  is  the  publication  of  29  country  health 

profiles for 2021 in the second half of November 2021.  

The total EU contribution to OECD amounts to EUR 1 500 000.  

The total EU contribution to the Observatory amounts to EUR 950 000.  

For more information on State of Health in the EU: https://ec.europa.eu/health/state/summary_en  

Brief description of activities  

The recurring State of Health in the EU cycle consists of four main stages: 

1)  The joint  OECD-Commission report  Health at a Glance: Europe kicks off each  State of 

Health  in  the  EU  cycle  with  a  cross-cutting,  cross-country  assessment  of  national  health 

systems’ performance in the EU. 

2)  Individual country health profiles, adapted to the specific context and situation of each EU 

country, assess the strengths and challenges in their respective health systems. 

3)  A companion report, published alongside the country health profiles, provides an overview 

of the country profiles.   

4)  At  the  close  of  the  two-year  cycle,  health  authorities  in  EU  Member  States  can  request 

voluntary  exchanges  with  the  experts  behind  the  State  of  Health  in  the  EU,  to  discuss 

findings and potential policy responses. 

Through this  initiative,  the Commission brings together internationally  recognised expertise and 

provides  Member  States  with  evidence  relevant  to  their  specific  context,  without  making 

comparisons between countries. The cycle helps Member States learn from one another by sharing 

knowledge  and  best  practices.  It  also  provides  a  reliable  international  expert  assessment  of  the 

health  situation  and  health  systems  in  Member  States  providing  benchmarks  to  facilitate  health 

sector reforms and enable informed decision-making at national level. 

Specific results 

25 

 
 
State  of  Heath  in  the  EU  provides  extensive  data  and  comparative  analyses  that  can  be  used  to 

identify strengths and opportunities for improvement in EU health systems. It helps EU national 

authorities  to  design  more  effective  policies  to  improve  the  health  of  their  citizens  and  the 

performance of their health systems.  

In  turn,  the  reports  provide  DG  SANTE  with  data  and  policy  analysis  to  support  EU-level 

cooperation  in  the  area  of  health.  This  information  also  feeds  into  the  analytical  phase  of  the 

European  Semester,  informing  its  country  reports  with  sound  cross-EU  and  country-specific 

insights. 

The Health at a Glance: Europe 2020 report provided a much-needed preliminary assessment of 

the effectiveness of European countries’ COVID-19 containment and mitigation measures, health 

systems capacity, testing strategies, measures to protect vulnerable groups and continuity of care 

for  non-COVID  patients.  The  report  provides  policy  makers  with  high-quality  evidence  from 

which  they  can  draw  valuable  lessons.  It  provides  a  basis  to  develop  more  effective  policy 

measures and build health system resilience, both in the short and the long term. It also assesses 

the  health  impact  of  air  pollution,  and  provides  comparative  analyses  of  the  health  status,  risk 

factors, health expenditure, quality and access to care in 36 European countries. 

4.2 OECD- Support to develop patient-reported measures (PaRIS)43 

More information about the PaRIS report is available on the OECD website44.  

Background 

The  patient-reported  indicator  surveys  (PaRIS)  initiative  builds  capacity  to  measure  patient-

reported  indicators  and  compare  them  across  countries.  It  also  aims  to  encourage  international 

alignment of patient-reported indicators to enable shared learning, development and research.  

The  PaRIS  initiative  develops,  pilots  and  implements  new  patient-reported  indicators  of  health 

system  performance,  specifically  patient-reported  experience  measures  (PREMs)  and  patient-

43 The full title is ‘Measuring What Matters: the Patient-Reported Indicator Surveys - Patient-reported indicators for 
assessing health system performance’.  
44 http://www.oecd.org/health/health-systems/Measuring-what-matters-the-Patient-Reported-Indicator-Surveys.pdf  

26 

 
 
 
                                                      
reported outcome measures (PROMs). It helps health systems to become more people-centred by 

providing systematic, internationally standardised information on what matters most to patients. 

The 2019 action enabled the OECD to prepare the report ‘Measuring What Matters: the Patient-

Reported Indicator Surveys Patient-reported indicators for assessing health system performance’, 

which defines and collects internationally comparable patient-reported indicators of health system 

performance45.  

The EU contribution amounted to EUR 500 000. 

Brief description of activities  

For the 2019 edition of PaRIS, groups of international experts were brought together to agree on 

appropriate  health  system  performance  indicators  to  be  reported  by  patients  with  specific 

conditions or procedures. Three international working groups worked on sets of indicators in the 

areas  of  hip-  and  knee  replacements,  breast  cancer  surgery  and  mental  health.  Using  feedback 

from  the  working  groups,  the  OECD  started  collecting  data  on  condition-specific  performance 

indicators. 

The  action  supported  a  pilot  to  test  new  indicators  on  patient-reported  experience  measures 

(PREMs)  and  patient-reported  outcome  measures  (PROMs)  to  define  new  and  more  reliable 

indicators of health outcomes and health system effectiveness.  

The action developed expertise on assessing the performance of health systems. It also helped to 

draw  lessons  from  recent  experience  and  EU-funded  research  projects  and  to  build  further  on 

country-specific and cross-country knowledge to inform national and European-level policies.  

PaRIS’ added value for the OECD and the EU was to help Member States exchange best practices 

through knowledge-sharing  and benchmarking networks, to  enable  informed decision-making at 

national  and  regional  level.  To  ensure  the  comparability  of  data,  PaRIS  could  only  be  done  by 

international  and  supranational  organisations.  The  cooperation  between  the  OECD  and  the  EU 

ensured maximum value for both organisations and their Member States. 

45More information is available at: 
https://ec.europa.eu/health/sites/health/files/systems_performance_assessment/docs/prims_en.pdf  

27 

 
 
 
 
 
                                                      
 
Specific results  

In 2019, the OECD developed an implementation  plan for a new  PaRIS  international  survey  on 

outcomes  and  experiences  of  patients  with  long-term  conditions.  Member  States  can  use  the 

results to assess their capacity to deliver positive health outcomes, and improve their policies. The 

comparability  of  the  indicator  allows  countries  to  share  best  practices,  information  and 

experiences with their peers.  

The action helped policy makers in two ways: 

- 

In areas where patient-reported indicators for specific conditions already exist, the first work 

stream  helped  countries  accelerate  the  adoption  and  reporting  of  validated,  standardised, 

internationally comparable patient-reported indicators. 

-  To  increase  understanding  on  the  outcomes  and  experiences  of  people  with  one  or  more 

chronic conditions, the second work stream developed a new international survey focusing on 

adults  with  one  or  more  chronic  conditions  who  are  receiving  primary/ambulatory  care 

services.  

28 

 
 
 
 
 
5. CALLS FOR TENDERS 
Objective 3: Contributing to innovative, efficient and sustainable health systems  

5.1 Medical devices - Information campaign contracts  

Background 

These  actions  respond  to  thematic  priority  3.6  of  Annex  I  to  the  Programme  Regulation: 

‘Implementation  of  Union  legislation  in  the  field  of  medical  devices,  medicinal  products  and 

cross-border healthcare’. The service contracts46 helped finance a communication and information 

campaign on medical devices, to support the new medical devices  ((EU) 2017/745) and in vitro 

medical devices (Regulation (EU) 2017/746). The campaign ran from 2018 to 2019.  

The EU contribution amounted to EUR 449 856.  

Brief description of the activities  

The  campaign  targeted  market  players,  healthcare  professionals,  health  institutions  and  patients. 

Its overall purpose was to inform and raise awareness about the requirements of new regulations 

on medical devices (MD) and in vitro medical devices (IVD) before they enter into force in May 

2021 and May 2022 respectively, to avoid any disruption to the MD and IVD markets. 

Specific results 

The second phase of the campaign47 involved  an evaluation  of the previous campaign, database 

updates, producing tailored materials, a newsletter and a media mapping, organising webinars and 

participating in relevant events. 

The key results include:  

• 

• 

• 

An online information hub where stakeholders can find relevant, up-to-date material, 

(https://ec.europa.eu/health/md_newregulations/getting_ready_en)  

Over 2 30 stakeholders’ contacts in and outside the EU (mapping), 

A total of 106 910 views of the medical devices webpage between June and October 

2020, 

46 Framework Contract FWC CHAFEA-2017-AGRI-06 Lot 4. 
47 
GROW.pdf 

https://www.camd-europe.eu/wp-content/uploads/2020/01/2-MD-Campaign-Achievements-GOPAcom-for-DG-

29 

 
 
 
 
 
 
                                                      
• 

• 

Mapping of specialised media (approx. 1 500 contacts in and outside the EU) and 

media monitoring, 

Participation in key medical events. 

The campaign produced the following material: 

• 

• 

• 

Three newsletters, which were sent to over 13 000 contacts 

Three webinars  

Eight factsheets available on the website and disseminated to stakeholders, translated 

into all EU languages and Chinese, Turkish and Japanese. 

5.2 Investing for a healthy and inclusive EU 

Background 

The report ‘Investing for a healthy and inclusive EU’ summarises the results of a two-year study 

into  the  extent  and  outcomes  of  health  investments  supported  by  the  European  Structural  and 

Investment  (ESI)  Funds  in  2014-2020  (particularly  the  European  Social  Fund  (ESF)  and  the 

European Regional Development Fund (ERDF)). Using desk research, interviews and stakeholder 

workshops,  the  study  highlights  the  successes  and  good  practices  observed,  and  identifies 

remaining challenges and prospects for the future. 

Brief description of activities  

The  ESI  Funds  for  Health  project’s  goal  was  to  identify  and  classify  all  health-related  projects 

supported by ESI Funds across the EU-28 and assess their contribution to EU health policy goals. 

The project  also aimed to highlight  and share good practices, success  factors and lessons learnt, 

and  to  build  capacity  across  the  EU  for  investing  in  health.  The  approach  provided  some 

interesting insights and lessons about data availability and the links between projects and policy. 

Specific results 

The  ESI  Funds  for  Health  project  mapped  and  assessed  more  than  7 000  health-related  projects 

supported  by  the  ESI  Funds  during  the  first  4  years  of  the  2014-2020  spending  period.  The 

projects  were  on  key  EU  health  policy  objectives:  access  to  healthcare;  the  reform  of  health 

systems;  the  uptake  of  e-health  and  digital  solutions;  research  and  innovation  in  health;  health 

promotion  and  healthy  ageing;  and  support  for  the  health  workforce.  The  project  also  helped 

30 

 
 
inform the beneficiaries on how to use the funds effectively by organising 6 workshops in various 

EU countries and a final conference in Brussels.  

This final report summarises the key outcomes of the two-year project. Its methods included desk 

research and analysis on the use of ESI Funds for Health investments, and input from stakeholders 

across EU Member States. It presents key findings on the use of ESI Funds to support each of the 

six  health-related  themes48,  success  factors  and  challenges,  cross-thematic  and  country-specific 

conclusions and recommendations for the next programming period. 

48  Improving  access  to  healthcare;  reform  of  health  systems;  uptake  of  e-health  and  digital  solutions;  research  and 
innovation in health; ageing and health promotion, including disease prevention, the promotion of active and healthy 
ageing and a healthy workforce and health workforce. 

31 

 
 
 
 
 
                                                      
6.  HIGHLIGHTS  OF  CO-FUNDED  ‘CROSS-CUTTING’  AND 
‘OTHER’ ACTIONS 

6.1 Dissemination activities carried out in 2019 
In 2019, Chafea carried out dissemination activities to raise the visibility of the results and successes of the 

3rd health programme, to promote the Commission’s specific communication priorities, and to reach even 

more  potential  programme  beneficiaries.  Details  on  these  activities  can  be  found  in  Chafea’s  2019 

dissemination activity  report for the third EU health programme. The  health  programme  conference held 

on 30 September 2019 was the major event of the year, with over 350 attendees. It aimed: (1) to highlight 

the success stories of the 3rd health programme; and (2) to present EU health funding opportunities under 

the post-2020 multiannual financial framework. In cooperation with the health programme’s national focal 

points, Chafea organised several information days (in Bosnia and Herzegovina, Czechia, Greece, Ireland, 

Italy, Malta, Poland and Sweden) with over 250 participants, on topics connected with the national policy 

priorities.   

Chafea also actively participated in some major European public health conferences attended by scientists 

and health professionals. For example:  

  19th International Foundation on Integrated Care, 1-3 April 2019, San Sebastian49  

  EU health programme conference, 30 September 2019, Brussels50  

  22nd European Heath Forum Gastein, 2-4 October 201051 with stand  

  12th European Public Health Conference 2019, 20 -23 November, Building bridges for solidarity 

and public health, Marseille, France52. Organised lunch symposium on ‘How can we join forces to 

engage  in  multi-stakeholder  actions  to  reach  optimal  influenza  vaccination  coverage  rates  in 

Europe?’.  

Online dissemination activities included over 120 cross-linked news items on Chafea’s website with social 

media promo, webinars on funding opportunities, dissemination guidance for beneficiaries, and an upgrade 

of the database’s download features.  

49https://integratedcarefoundation.org/events/icic19-19th-international-conference-on-integrated-care-san-sebastian-
basque-country  
50 https://ec.europa.eu/chafea/health/newsroom/news/18032019/programme_en.htm  
51 https://www.ehfg.org/archive/2019/conference/ 
52 https://ephconference.eu/conference-2019-marseille-271  

32 

 
 
 
                                                      
Web  publications (available  to  print  on demand)  produced by  Chafea  included a  booklet  ‘Health for  the 

EU’ presenting the programme’s success stories53, and two information sheets on e-health54 and on frailty55 

available in all 23 EU languages.  

In  2019,  Chafea  spent  EUR  625.035,58  on  dissemination  activities.  This  was  for  organising  events:  the 

costs  of  venues,  renting  space  for  stands  at  exhibitions,  travel  and  accommodation  of  experts  and  the 

production and printing of materials.  

6.2 Other actions  
Background information 

Eurostat, the EU’s statistical office, is the main source of comparable EU heath data. Its mission is based 

on the framework regulation on health statistics and derived legal acts56.  

Brief description 

Eurostat provides two kinds of health statistics, administrative, such as cause of death statistics, and self-

reported data, e.g. from the European Health Interview Survey (EHIS) or the Minimum European Health 

Module (MEHM) of the EU-SILC survey. Themes covered by these statistics include: 

-  Health status, 

-  Health determinants, 

-  Health care expenditure, 

-  Health care resources and activities, 

-  Causes of death, 

-  Health and safety at work. 

Under the 2019 work programme, the Commission provided a sub-delegation to Eurostat on non-monetary 

healthcare statistics for morbidity (EUR 150 000) and for improving the consistency between EHIS and the 

EU-SILC 2022 Module on Health (EUR 300 000).  

https://op.europa.eu/en/publication-detail/-/publication/08e68564-67fe-11e9-9f05-01aa75ed71a1/language-

53 https://op.europa.eu/en/publication-detail/-/publication/98986869-e049-11e9-9c4e-01aa75ed71a1  
54 
en?WT.mc_id=Selectedpublications&WT.ria_c=19980&WT.ria_f=3171&WT.ria_ev=search  
55https://op.europa.eu/en/publication-detail/-/publication/b3cbce3e-5ccd-11e9-9c52-01aa75ed71a1/language-
en?WT.mc_id=Selectedpublications&WT.ria_c=19980&WT.ria_f=3171&WT.ria_ev=search   
56 https://ec.europa.eu/health/indicators_data/key_documents_en#anchor1  

33 

 
 
 
                                                      
6.2.1 Morbidity statistics 

Brief description 

Interest  in  morbidity  statistics  and  the  need  to  gather  evidence  to  inform  national  and  EU  policies  and 

initiatives has increased significantly. Disease-specific morbidity statistics should be produced based on an 

agreed  diagnosis-related  shortlist,  which  is  closely  linked  to  the  data  on  causes  of  death.  Morbidity 

statistics should also be reported regularly. Quantitative morbidity statistics are missing in evidence-based 

health  policy  decisions.  Increasing  the  use  of  information  from  current  data  collections  by  improving 

coordination  and  the  comprehensiveness  of  data  and  adding  additional  dimensions  of  data  analysis  is  of 

major importance for public health. 

The Commission provided a sub-delegated credit of EUR 150 000 to support ESTAT in this initiative, of 

which  EUR 145 610  has  been  used.  This  first  30%  payment  went  towards  work  carried  out  at  the 

contractor’s  premises  (corresponding  to  EUR 135 290)  and  onsite  measures  (up  to  EUR 10 320,  as 

necessary).  Given  the  changes  in  working  practices  due  to  the  COVID-19  pandemic,  further  onsite 

measures did not take place.  

• 

Title of the contract: Morbidity statistics (MORB2) 

The main objectives of the contract were:  

• 

• 

• 

• 

• 

To  provide  methodological  assistance to  Eurostat  and  countries  during  the  pilot MORB  data 

collection.  

To analyse the identified issues by the type of data source and to assess the quality of data and 

data sources based on metadata submitted.  

To analyse data submitted and identify possible underreporting and undercoverage.  

To  suggest  a  standard  method  to  collect  morbidity  indicators  and  calculate  epidemiological 

estimates. The suggested approach can vary for different diseases and different indicators, but 

it should enable a cross-country comparison.  

To prepare the final documents and guidelines for the data collection and data validation. 

Main outcomes of the project: 

1) 

Helpdesk  assistance  and  practical  support  were  provided  to  Member  States  during  the  pilot 

stage.  

2) 

Quality  and  appropriateness  of  data  sources  were  assessed  and  documented  in  updated 

guidelines.  

34 

 
 
 
3) 

Pilot  data  was  collected  and  validated  for  all  countries  except  Malta  and  Germany,  as  they 

requested an amendment that ran beyond the duration of the contract with Sogeti.  

4) 

Documents  and  guidelines  on  data  collection  and  data  validation  were  revised  and  updated 

based on the country experiences during the pilot exercise. 

6.2.2 Consistency between EHIS and EU-SILC Module on Health 2022 

Brief description 

The  project  assists  with  the  analysis  of  microdata  and/or  aggregated  data,  metadata,  quality  reports, 

questionnaires and other relevant documents from the European Health Interview Survey (EHIS).  It also 

deals with the comparison between health data and related questions from EHIS and the EU Statistics on 

Income and Living Conditions (EU-SILC). The project’s results will help prepare wave 4 of EHIS (2025) 

and the EU-SILC module on quality of life that will be conducted in 2022. 

With  the  sub-delegated  credit  of  EUR  300 000  from  the  Commission,  DG  SANTE  for  improving  the 

consistency  between  EHIS  and  the  2022  EU-SILC  Module  on  Health,  ESTAT  launched  a  specific 

contract  (fixed  price)  under  the  framework  contract  for  statistical  services  for  social  indicators,  Lot  1  – 

Support and helpdesk for the production of social statistics and indicators (07112.2016.003-2017.018). 

• 

Title of the contract: Support for methodological work and statistical analysis on the health-related 

information collected in various EU surveys and modules 

Main objectives of the contract: 

• Analysing the EHIS wave 3 microdata characteristics (response and non-response, proxy interview’s use, 

sample size, weights, sample structure, other technical variables, etc.). 

• Comparing the frequencies of each common variable of EHIS waves 2 and 3 in order to identify possible 

comparability issues. 

•  Employing  advanced  statistical  analysis  techniques  in  order  to  investigate  the  relationship  between 

specific health-related concepts (including the exploration of the association of GALI with other disability 

measures available from EHIS). 

• Supporting the preparation of the 2022 SILC module on quality of life (every 6-years). 

• Analysing the national implementation of the 2021 SILC module on children’s health and comparing it 

with that of 2017. 

35 

 
 
• Analysing the results and reports from the testing of the EHIS voluntary topics, including a summary of 

issues found during testing, conclusions from the analysis performed and recommendations for questions to 

be included in future EHIS waves. 

• Analysing the national EHIS wave 3 quality reports in order to describe the main aspects influencing the 

quality process of conducting the survey. 

• Updating and improving existing ‘Statistics Explained’ articles and drafting new articles that use or refer 

to health-related data from EU-SILC and EHIS. 

•  Assessing  the  2018  EU-SILC  ad  hoc  module  on  quality  of  life  and  housing  difficulties  (the  latter  are 

optional variables). 

Main outcomes expected by the end the project: 

• Statistical analysis plan for EHIS waves 2 and 3 data. 

• Statistical report on EHIS wave 3 microdata characteristics, comparison of frequencies of each common 

variable  of  EHIS  waves  2  and  3  and  related  conclusions,  advanced  analysis  techniques  applied  to  EHIS 

waves 2 and 3 microdata and related results. 

• Report describing the selection of SILC variables on quality of life in the 2022 every 6-year module. 

•  Report  describing  the  national  implementation  of  the  SILC  2021  module  on  children’s  health  and 

comparing the national implementation of the SILC 2017 module on children’s health. 

• Assessment document for EU-SILC 2018 ad hoc module. 

• Draft EHIS wave 3 EU quality report. 

• Draft EHIS ESMS metadata text ready for publication on the Eurostat website. 

• Report describing the testing of voluntary topics in EHIS wave 3 and presenting results and conclusions 

from the testing as well as recommendations for future EHIS waves. 

• Up to 20 Statistics Explained articles updated, up to five articles improved and three new articles drafted; 

around four Statistics Explained methodological articles updated or improved. 

6.3 Final evaluation of the third health programme 
Article 34 of the Financial Regulation requires that the Commission monitors, evaluates and reports on the 

implementation  of  the  spending  programme  actions.  In  line  with  this  and  with  the  better  regulation 

36 

 
 
guidelines,  the  Commission  started to  prepare  the  final  evaluation  of  the  third  health  programme  (2014-

2020) in 2020, covering all Member States and other participating countries.  

The  Commission  will  publish  the  results  of the  evaluation  in  the  form  of  a  staff  working  document  and 

ensure its dissemination. The results will also feed into the implementation of the  2021-2027 EU4Health 

programme. 

7. IMPLEMENTATION OF ANNUAL WORK PROGRAMME 2019  

7.1 Calls for proposals 
Chafea launched calls/invitations for proposals for projects, joint actions, ERNs project grants and 

specific  grants  for  NGOs  from  May  2019  on  the  Funding  &  tender  opportunities  -  Single 

Electronic Data Interchange Area (SEDIA).  

The sections below describes the results of each of the calls.  

7.1.1 Joint Actions 

The  grants  for  actions  co-financed  with  Member  State  authorities  are  ‘actions  having  a  clear 

Union  added  value  co-financed  by  the  competent  authorities  of  Member  States  responsible  for 

Health or by public sector bodies and non-governmental organisations, acting individually or as 

a network, mandated by these competent authorities57’. 

These  grants therefore  enable the national  authorities of  EU  and  other countries participating in 

the programme and the European Commission to take forward work on jointly identified issues.  

The maximum EU contribution is 60%, but it can go up to 80% for proposals that meet the criteria 

for exceptional utility.  

Countries  participating  in  the  third  health  programme  nominate  competent  authorities  or  other 

bodies who are then invited to submit a proposal under the direct grant procedure. 

In  2019,  three  joint  actions  were  published  for  a  total  of  EUR 14 992 063,  addressing  the 

following first, second and third health programme objectives: 

57 Definition of a joint action according to Article.7 2(a) of the Regulation for the third Health Programme 2014-2020, 
https://ec.europa.eu/health/funding/programme_en  

37 

 
 
                                                      
Under  Objective  1,  Promote  health,  prevent  diseases  and  foster  supportive  environments  for 

healthy  lifestyles  taking  into  account  the  'health  in  all  policies'  principle,  a  joint  action  to 

implement validated best practices in  the field of nutrition was launched to increase the offer of 

healthier  processed  food  and/or  reduce  salt,  sugar  and  saturated  fat  from  the  processed  food 

available in EU supermarkets.  

Under Objective 2, Protect Union citizens from serious cross-border health threats, a joint action 

was launched to strengthen health preparedness and the response to biological and chemical terror 

attacks. It aimed to detect threats and assess risks for health-related terrorism acts while bridging 

gaps between public health, security and civil protection sector partners. 

Under  Objective  3,  Contribute  to  innovative,  efficient  and  sustainable  health  systems,  a  joint 

action  was  launched  on  digitally-enabled,  integrated  person-centred  care.  It  aimed  to  help 

healthcare  authorities  reform  their  healthcare  systems  by  developing  the  capacity  to  implement 

integrated  care  using  a  bottom-up  approach.  It  was  based  on  the  main  design  principles  and 

building  blocks  for  integrated  care  identified  by  the  health  systems  performance  assessment 

(HSPA) expert group58. 

The table below briefly describes each joint action by objective and thematic priority:  

Financial 

instrument 

Joint action by objective 

Amount  committed  in 

EUR 

Objective: 

1 

Objectives' 

description: 

1.  Promote  health,  prevent  diseases  and  foster 

supportive  environments  for  healthy  lifestyles 

taking  into  account  the  'health  in  all  policies' 

principle 

Thematic priority: 

1.1  Cost-effective  promotion  and  prevention 
measures  in  line,  in  particular,  with  the  Union 
strategies on alcohol and nutrition 

User reference 

Title 

Amount committed 

58 Expert group on Health Systems Performance Assessment (HSPA): 
https://ec.europa.eu/health/systems_performance_assessment/policy/expert_group_en  

38 

 
 
 
 
 
                                                      
951202 

-  HP-JA-

2019 

Joint  action on implementation  of validated best 
practices 

6 000 000 

Objective: 

2 

Objectives' 

description: 

Thematic priority: 

Protect  Union citizens from  serious cross-border 
health threats 

2.2  Support  capacity-building  against  health 
threats  in  Member  States,  including,  where 
appropriate,  cooperation  with  neighbouring 
countries 

Amount committed 

User reference 

Title 

4 992 837 

951442 

-  HP-JA-

2019 

Joint  action  on  strengthened  international  health 
regulations and preparedness in the EU 

Objective: 

3 

Objectives' 

description: 

Contribute 
sustainable health systems 

to 

innovative, 

efficient 

and 

Thematic priority: 

3.4 

User reference 

Title 

101003855- 

  HP-

JA-2019 

Joint  action  on  implementation  of  digitally-
enabled integrated person-centred care  

Chafea 

- 

total 

committed  for  all 

joint actions 

7.1.2 Project grants 

Amount committed 

3 999 226 

14 992 063 

Project grants were awarded to actions involving 79 organisations - mainly public health bodies, 

research institutions and non-governmental organisations. The maximum EU contribution is 60% 

of eligible costs, but it can go up to 80% for proposals that meet the criteria for exceptional utility.  

Chafea launched the first call for proposals for projects in May 2019 in the following areas: 

39 

 
 
 
 
 
 
 
 
 
Rare disease registries  for the European Reference Networks  (ERNs)  and  stakeholder actions to 

implement the EU guidelines on prudent use of antimicrobials in human health.  

Overall,  23  proposals  were  submitted  in  response  to  the  two  calls  for  proposals  for  projects,  of 

which two were below the threshold and 21 reached the threshold.  

7.1.3  Project  grants  -  Rare  disease  registries  for  the  European  Reference 
Networks 

The proposed action aims to support the development of rare disease registries for the ERNs.  Its 

activities  included  building  and  developing  rare  disease  patient  registries  for  ERNs,  and  further 

developing  the  quality  control  of  existing  registries.  Patient  registries  and  databases  are  of  key 

importance  for  developing  clinical  research  on  rare  diseases,  and  improving  patient  care  and 

healthcare planning. They are the best way of pooling data to achieve a sufficient sample size for 

epidemiological  and/or clinical  research. Registries serve as a recruitment tool for the launch of 

studies focusing on disease aetiology, pathogenesis, diagnosis or therapy. 

Five ERNs already received financial support under the health programme (annual work plan for 

2016) and are currently developing a comprehensive approach for rare disease registries covering 

their entire ERN, following JRC standards and tools. 

Objectives: 

The main objectives of the projects for rare disease registries for ERNs are: 

- 

to  build,  upgrade,  link  and  make  interoperable  registries  covering  the  diseases  and 

conditions of each ERN, thus linking and making visible patient cohorts at European level 

in  order  to  follow  up  the  natural  course  of  diseases  with  sufficient  patient  data,  also  by 

registering all individual RD registries of the ERNs on the EU RD Platform; 

-  based  on  the  above  registration,  to  develop  a  comprehensive  approach  for  rare  disease 

registries covering the respective ERNs following the standards and tools provided by the 

EU RD Platform. 

The expected outputs are: 

- 

setting up new or improving the existing rare disease registries; 

-  better coordination and cooperation among rare disease registries; 

- 

- 

increased interoperability between rare disease registries; 

cost-effective building of registries by avoiding fragmentation and duplication of work; 

40 

 
 
-  better visibility of rare disease registries and, in particular, of those used and enhanced by 

ERNs. 

Responding to the above call, 21 proposals were received out of which 19 were deemed eligible. 

According  to  the  financing  decision,  each  network  could  receive  up  to  EUR  200  000  per  year. 

However,  not  all  networks  requested  the  full  available  amount  (see  below  table).  The  projects 

began in early 2020 and most will run for 36 months.  

The  maximum  overall  EU  funding  for  the  ERNs  project  grants  was  EUR  3 800 000.  The  table 

below sets out the EU contribution allocated to each awarded project. 

Financial instrument  ERN project grants by 

Objective: 
Objectives' 
description: 

Thematic priority: 

User reference 

HP-PJ-2019- 947664 
EPICARE-GRANT 
(2 years duration) 
HP-PJ-2019- 947629 
PETER 
(3 years duration) 
HP-PJ-2019-947662 
ERNICA registry  
(3 years duration) 
HP-PJ-2019- 947690-
ERN-Skin 
REGISTRY 
(3 years duration) 
HP-PJ-2019- ERN-
RND Registry 
947588 
(3 years duration) 
HP-PJ-2019- 
TogethERN 
ReCONNET 
947700 
(3 years duration) 

healthcare 

objective 
4 
4.  Facilitate  access  to  better  and 
safer 
for  Union 
citizens 
4.1  Support  the  establishment  of 
a  system  of  European  reference 
patients  with 
networks 
conditions 
highly 
specialised care… 
Title 

requiring 

for 

operational 

An 
EPICARE 
registry  for  all  rare  and  complex 
epilepsies 
PaEdiatric 
European registry  

transplantation 

EU 
contribution 
in EUR 
199 878.00 

Total 
amount in 
EUR 

333 130.59 

199 981.42 

333 303.20 

ERNICA  registry  for  improving 
care 

200 000.00 

346 145.00 

Interoperable  ERN  on  rare  and 
undiagnosed skin disorders 

200 000.00 

333 333.33 

The ERN-RND rare neurological 
disease registry 

200 000.00 

333 786.50 

199 950.00 

333 251.50 

a 
TogethERN  ReCONNET: 
European  registry  infrastructure 
for data harmonisation in 
rare  and  complex  connective 
and  musculoskeletal 
tissue 

41 

 
 
 
 
 
 
 
 
 
 
 
diseases 

Starting  an  adult  rare  tumour 
European registry 

199 999.00 

333 331.75 

REDgistry:  An 
interoperable 
sustainable  European  rare  eye 
disease registry 

197 748.84 

329 581.40 

European  rare  blood  disorders 
platform 

199 371.00 

329 615.35 

European  registry  for  rare  bone 
and mineral conditions 

200 000.00 

333 333.32 

ERN CRANIO registry 

200 000.00 

345 503.00 

MERITA project: a metadata 
registry for the RITA ERN 

195 972.00 

261 187.00 

HP-PJ-2019- 
STARTER 
947604 
(3 years duration) 
HP-PJ-2019- 
REDgistry 
947444 
(3 years duration) 

HP-PJ-2019- ENROL 
947670 
(30 months duration) 
HP-PJ-2019- EuRR-
Bone 
946831 
(3 years duration) 

HP-PJ-2019- ERN 
CRANIO registry  
947699 
(3 years duration) 

HP-PJ-2019- 
MERITA 
947180 
(3 years duration) 

HP-PJ-2019- ILIAD 
947617 
(3 years duration) 

ILIAD Rare diseases patient 
registry: an international library 
of intellectual disability 
and anomalies of development 

HP-PJ-2019- EURO-
NMD Registry 
947598 
(3 years duration) 

Patient-centred  and  interoperable 
registry 
rare 
for 
neuromuscular diseases 

hub 

198 119.00 

363 832.42 

200 000.00 

551 724.17 

HP-PJ-2019- ERN 
eUROGEN registry 
946157 
(3 years duration) 

HP-PJ-2019- 
GENTURIS registry 
947257 
(3 years duration) 

ERN eUROGEN Registry for 
rare urogenital diseases 

200 000.00 

333 333.61 

The ERN genetic tumour risk 
syndromes registry 

199 167.00 

331 946.10 

42 

 
 
 
 
 
 
 
 
 
 
 
 
HP-PJ-2019- 
VASCERN Registries 
947651 
(3 years duration) 

HP-PJ-2019- R-
LIVER 
945761 
(3 years duration) 

HP-PJ-2019- 
GUARD-Heart 
Registry 
946148 
(3 years duration) 

TOTAL ERN- HP-
PJ-2019 

VASCERN Registries59 

196 961.13 

328 312.11 

(R-Liver) Registry for rare liver 
diseases 

200 000.00 

333 333.89 

The Heart-Core Registry: a 
gateway to uncommon and rare 
diseases of the heart. 

199 999.00 

333 331.75 

3 787 146.39 

6 521 315.99 

7.1.4  Grants  for  stakeholder  projects  to  implement  the  EU  guidelines  on 
prudent use of antimicrobials in human health  

The second call for proposals was for actions by stakeholders to implement the EU guidelines on 

prudent use of antimicrobials in human health. It aimed to involve European-level stakeholders in 

promoting, disseminating and applying the EU guidelines on the prudent use of antimicrobials in 

human health  to  the target  groups identified in  the  guidelines,  e.g.  prescribers (doctors, hospital 

clinicians),  pharmacists,  nurses,  infectious  disease  specialists  and  those  responsible  for  the 

management of health systems. 

Objectives and expected results:  

The  call  for  projects  (stakeholder  actions)  mainly  focused  on  the  implementation  of  the  EU 

guidelines on prudent use of antimicrobials in human health: 

-  to  raise  awareness  on  the  guidelines  and  encourage  their  direct  application  by  healthcare 

practitioners and members of the stakeholder organisations; 

59 This project proposal concerns the registry needs of VASCERN, the ERN on rare multisystemic vascular diseases. 

43 

 
 
 
 
 
 
  
 
 
 
 
                                                      
-  to  change  practices  on  antimicrobial  prescription  and  dispensing  among  members  of  the 

stakeholder organisations involved (in the project) in line with the guidelines; 

- to reduce the inappropriate use of antimicrobials in human health. 

The activities should enable stakeholder organisations to take further action on AMR in line with 

the EU guidelines on prudent use of antimicrobials in human health. The action will engage with 

professional groups and address settings that require specific attention. It will develop measures to 

implement the guidelines adapted to the needs of the job roles and settings (e.g. hospital, primary 

care long-term care) involved. 

Three  proposals  were  evaluated  but  only  one  was  retained  for  funding  as  shown  in  the  table 

below:  

Financial 
instrument 
Objective: 
Objectives' 
description: 
Thematic priority: 

User reference 
HAPPY 
PATIENT 
900024 

Project grants by objective 

improve 

4 
4.  Facilitate  access  to  better  and  safer 
healthcare for Union citizens 
4.4 
antimicrobial  agents  and 
practices 
that 
resistance 
Title 
Health alliance for prudent prescription and 
yield  of  antibiotics  in  a  patient-centred 
perspective 

the  prudent  use  of 
reduce 
the 
antimicrobial 

increase 

Amount committed in EUR 
1 987 001.00 

7.1.5 Operating grants 

Operating  grants  are  awarded  to  non-governmental  bodies  that  pursue  one  or  more  of  the  health 

programme’s specific objectives. They must: 

  be non-governmental; 

  be non-profit-making and independent of industry, commercial and business or other 

conflicting interests; 

  work in the public health area; 

  play an effective role in civil dialogue processes at EU level; 

  pursue at least one of the programme’s specific objectives; 

  be active at EU level and in at least half of the Member States; and 

  have a balanced geographical coverage of the EU. 

44 

 
 
 
 
 
 
 
 
 
 
All  activities  within  the  scope  of  Annex  1  of  the  Regulation  establishing  the  third  health 

programme can be funded by a specific grant awarded under a framework partnership agreement 

(FPA) for the functioning of non-government bodies (operating grants).  

Of  those  EU  umbrella  organisations  that  signed  a  FPA  in  2017  for  2018-2021,  priority  areas 

included  prevention  and  health  determinants,  chronic  diseases,  cancer,  dementia,  rare  diseases, 

HIV/AIDS, tuberculosis and hepatitis, access to healthcare and substances of human origin. 

FPA recipients were invited to apply for a specific grant agreement (SGA) to cover their operating 

costs for 2019. The maximum EU contribution is 60% of the annual operating costs, but it can go 

up to 80 % for proposals that meet the criteria for exceptional utility.  

In  2019,  of  the  14  operating  grants  signed,  seven  (48%)60  fulfilled  the  exceptional  utility 

conditions.  

At the end of 2019, the grant process was completed, representing EUR 5 434 283.00 in funding.  

The table below lists all operating grants funded by objective and priority. 

Financial 
instrument 
Objective: 
Objectives' 
description: 

Thematic priority: 

User reference 

881531- EUPHA 
SGA-2019 
881539 - SFP 
SGA 2019 

Operating grants by objective 

Amount committed in 
EUR 

1 
1.  Promote  health,  prevent  diseases 
and foster supportive environments for 
healthy  lifestyles  taking  into  account 
the 'health in all policies' principle 

1.1  Cost-effective  promotion  and 
prevention  measures 
in 
particular,  with  the  Union  strategies 
on alcohol and nutrition (…) 
Title 

line, 

in 

European Public Health Association 
(EUPHA) 2019 
Preventing 
chronic 
diseases through smoking prevention - 
2019 annual work plan for the Smoke 
Free Partnership 

cancer 

and 

Amount committed 

361 914.00 

470 013.00 

60  Operating  grants,  SGA  2019  with  EC  funding  higher  than  60%:  Smoke  Free  Partnership,  Correlation  Network, 
AIDS  Action Europe, European Network for Smoking prevention, European Public Health  Alliance, SHE  Network 
and Thalassaemia in Action. 

45 

 
 
 
 
 
                                                      
414 845.00 

585 000.00 

358 660.00 

2 191 232. 00 

Amount committed 

105 691.00 

294 100,00 

238 395.00 

638 186.00 

Amount committed 

455 310.00 

318 868.00 

774 178.00 

Amount committed 

200 640.00 

200 640.00 

881565 - ENSP - 
SGA-2019 

881533 – EPHA - 
SGA-2019 
881568 – SHE - 
SGA-2019 
Total 
Thematic priority: 

User reference 
881529- TBEC - 
SGA-2019 
882331- AAE - 
SGA-2019 
881545-CN- SGA-
2019 
Total 
Thematic 
priority: 

User reference 
881525 - AE2019 - 
SGA-2019 
881569- ECL 
SGA-2019 

Total 
Objective: 
Objectives' 
description: 
Thematic priority: 

User reference 
882339  - SGA-
2019 

Total 
Objective: 
Objectives' 
description: 
Thematic priority: 

European  Network  for  Smoking  and 
Tobacco Prevention – Paving the way 
for a tobacco free Europe 
European  Public  Health  Alliance 
(EPHA SGA 2019) 
Schools 
Foundation 

in  Europe 

health 

for 

such 

1.3  Support  effective  responses  to 
communicable  diseases 
as 
HIV/AIDS, tuberculosis and hepatitis 
Title 
TBEC:  strengthening  TB  response  in 
the WHO Europe region 
AIDS  Action  Europe 
together 
Correlation 
Reduction Network 

European  Harm 

-  Stronger 

- 

Support 

cooperation 

1.4 
and 
networking in the Union in relation 
to  preventing  and  improving  the 
response to chronic diseases 
Title 
Alzheimer Europe 

Cancer 

European 
-
Collaborating  for  impact  in  cancer 
control (2019) 

Leagues 

3 
3. Contribute to innovative, efficient 
and sustainable health systems. 
3.6 
of  Union 
Implementation 
legislation  in  the  field  of  medical 
devices, medicinal products and cross-
border healthcare 
Title 
A plan for action: Ensuring equitable, 
responsibly  used 
affordable 
medicines in the European Union 

and 

4 
4. Facilitate access  to  better and safer 
healthcare for Union citizens 
4.2 Coordinated action at  Union level 
in  order  to  effectively  help  patients 

46 

 
 
  
 
  
 
  
 
 
 
 
 
 
 
affected by rare diseases 
Title 
Eurordis Rare Diseases Europe SGA 
2019 

Amount committed 

1 058 520.00 

THALassaemia in action 2019 

257 027.00 

Implementation 

4.5 
of  Union 
legislation  in  the  fields  of  human 
tissues  and  cells,  blood,  human 
organs,  medical  devices,  medicinal 
products, and patients’ rights in cross-
border health care 
Title 
High-quality blood  stem cell products 
for  all  patients 
in  need,  while 
protecting the rights and welfare of the 
volunteer donors 

1 315 54700  

Amount committed 

314 500.00 

314 500.00 
5 434 283.00 

User reference 
881554 - 
EURORDIS SGA 
2019  
881566 – 
THALIA SGA 
2019  
Total 
Thematic priority: 

User reference 
881553 - 
SAVDON - SGA-
2019 

Total 
Chafea – total 
committed for all 
operating grants 

7.1.6 Direct grant agreements and Presidency conferences 

Direct grant agreements can be awarded to international organisations active in the area of public 

health61  for  specific  activities  requiring  organisations  with  particular  technical  competence, 

specialisation  or  administrative  powers,  on  the  condition  that  the  activities  concerned  are  not 

included in a call for proposals.  

Funding  for  actions  with  international  organisations  will  be  allocated  exclusively  through  grant 

agreements without a call for proposals on topics specifically identified in the work programme. 

The maximum EU contribution is 60%. 

In 2019, Chafea signed four direct grant agreements with the WHO, the OECD and Unicef for a 

total amount of EUR 5 750 000. 

61 Article 195(f) of Regulation (EU, Euratom) 2018/1046. 

47 

 
 
  
 
  
  
 
 
                                                      
The table below lists all direct grant agreements per objective and priority. 

Financial 
instrument 
Objective: 
Objectives' 
description: 

Direct grant agreements by objective 

Amount committed 
in EUR 

3 
Contribute  to  innovative,  efficient  and  sustainable 
health systems 

Thematic priority: 

3.7.  Foster  a  health  information  and  knowledge 
system  to  contribute  to  evidence-based  decision-
making  

User reference 

Title  

2019 53 03 

Objective: 
Objectives' 
description: 
Thematic priority: 

User reference 
2019 53 01 

Thematic priority: 

User reference 
2019 53 02 

Total 
Objectives: 
Objectives' 
description: 

State of Health in the EU cycle –               
Direct grant agreement OECD 
3. 
Contribute  to  innovative,  efficient  and  sustainable 
health systems 
3.7.  Foster  a  health  information  and  knowledge 
system  to  contribute  to  evidence-based  decision-
making 
Title 
State of Health in the EU cycle – Direct grant to 
the European Observatory on Health Systems and 

Policies - a WHO hosted partnership  

3.7.  Foster  a  health  information  and  knowledge 
system  to  contribute  to  evidence-based  decision-
making 
Title 
Support to OECD to develop and implement 
patient-reported measures  

1 and 2  
Promote  health,  prevent  diseases  and 
foster 
lifestyles 
supportive  environments  for  healthy 
taking  into  account  the  'health  in  all  policies' 
principle and 
Protect  Union  citizens  from  serious  cross-border 
health threats  

1 500 000.00 

Amount committed 
950 000.00 

Amount committed 
800 000.00 

Thematic priority: 
User reference 
2019 51 02 

Total 

1.1, 1.4, 2.2 
Title 
Support to children migrant populations in front 
line and transit countries 

Amount committed 
2 500 000.00 

2 500 000.00 

48 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL DIRECT 
GRANTS 

5 750 000.00 

7.1.7 Other direct award of grants 

Presidency conference grants – de jure monopoly  

The Presidency conferences financed under the 2019 work programme were organised under the 

Finnish and the Croatian Presidency of the EU Council.  

The ‘Economy of Wellbeing62’ conference was held on 18 September 2019 in Helsinki. It aimed 

to  generate  cross-sectoral  dialogue  on  various  themes  to  back  the  Council  conclusions  on  the 

economy of wellbeing.  

Under  the  Croatian  EU  Council  Presidency,  a  high-level  conference  on  organ  donation  and 

transplantation was supposed to be held in Zagreb on 16-17 and March 2020 but it was cancelled 

due to the COVID-19 outbreak.  

Financial 
instrument 

Objective: 
Objectives' 
description: 

Thematic priority: 

Health programme support to Presidency 
conferences by objective 

Amount 
committed in 
EUR 

1 
Promote  health,  prevent  diseases  and 
foster 
supportive  environments  for  healthy  lifestyles  taking 
into account the 'health in all policies' principle 
1.1  Cost-effective  promotion 
and  prevention 
measures  in  line,  in  particular,  with  the  Union 
strategies on alcohol and nutrition.  

User reference 

Title 

HP-PC-2019 
882415 

Objective: 

The Economy of Wellbeing 

4 

Amount 
committed 
100 000.00 

Objectives' 
description: 
Thematic priority: 

Facilitate  access  to  better  and  safer  healthcare  for 
Union citizens 
4.5  Actions  required  by,  or  contributing  to,  the 
implementation  of  Union  legislation  in  the  fields  of 

62 https://eu2019.fi/en/events/2019-09-18/high-level-conference-on-the-economy-of-wellbeing  

49 

 
 
  
 
 
 
 
 
 
 
 
 
 
                                                      
human  tissues  and  cells,  blood,  human  organs, 
medical  devices,  medicinal  products,  and  patients' 
rights in cross-border healthcare  
Title 

Organ donation and transplantation 

Amount 
committed 
13 687.18 

113 687.18 

User reference 

HP-PC-2020 
952841 

Chafea – total 
committed for 
Presidency 
conferences 

7.2 Beneficiaries 
From the overall 215 grants beneficiaries, their geographic distribution shows that 148 (69%) are from 

an  EU  15  country,  48  (22%)  from  those  countries  that  joined  the  EU  after  2004.  From  the  list  of 

countries  participating  to  the  3rd  health  programme,  7  are  from  Norway  (3%)  and  12  from  an  EU 

candidate country, a potential candidate, or from a European Neighbourhood Policy country (Serbia, 

Bosnia and Herzegovina and Moldova) (6%).  

Graphic 4: participation in the health programme - 2019 grants (%)  

Number beneficiaries

6%

3%

22%

69%

EU 15

EU 12

EEA

OTHER*

* EU candidate country, potential candidate or European Neighbourhood Policy country 

Chafea  organised  an  ‘information  days’  webinar  on  8  May  2019  to  promote  the  annual  work 

programme  for  2019.  It  included  information  on  funding  opportunities,  the  joint  action 

nomination  process  and  policy  priorities.  This  was  followed  by  a  joint  action  preparatory 

50 

 
 
 
  
 
 
workshop organised on 24 June 2019, which gathered 65 attendees (competent authorities of the 

countries participating in the programme only). A quality assurance workshop was then organised 

on 25 November 2019 to provide feedback to the joint action coordinators on the proposals.  

To promote participation in  the 2019 calls, the  national  focal  points63  for the  health  programme 

organised  eight  national  information  days64.  These  took  place  between  May  and  June  2019  in 

seven EU countries and one non-EU country participating in the third health programme. Chafea 

published  guidelines  for  applicants  on  its  participants  portal,  and  its  helpdesk  also  provided 

practical assistance. 

7.3 Experts evaluators 

Applications were evaluated in accordance with the rules and criteria set out in the AWP annual 

work programme 2019 and in the specific calls for proposals.  

The  proposals  submitted  under  different  calls  for  proposals  were  evaluated  by  external  experts 

(peer reviewers), drawn from a list established following the call for expressions of interest in the 

area of public health  –  EMI H2020 database65. The external  evaluation  of the call for proposals 

supports the efficient and transparent selection of proposals funded under the AWP 2019. 

Fourteen (14) external experts from 12 countries took part in the evaluation process for the award 

of the operating grants, projects and ERN grants and assessed the joint actions during the quality 

assurance workshop. 

The evaluation process took place in two stages: 

 

In  the  first  stage,  three  external  evaluators  assessed  each  proposal.  They  drew  up  a 

consolidated evaluation  report for each proposal  during the consensus meeting organised 

by Chafea.  

 

In  the  second  stage,  the  evaluation  committee  reviewed  the  work  of  the  external 

evaluators and drew up the final lists of proposals recommended for funding, together with 

the  reserve  lists.  The  evaluation  committee  comprised  representatives  from  the 

63 http://ec.europa.eu/chafea/health/national-focal-points/index_en.htm  
64 https://ec.europa.eu/chafea/health/national-info-days/2019-nid_en.htm  
65 EMI -https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/work-as-an-expert 

51 

 
 
 
                                                      
 
Directorate-General for Health and Food Safety (DG SANTE), the Directorate-General for 

Research and Innovation (DG RTD) and from Chafea.  

7.4 PRIZES – EU Health award for NGOS 
For the 2019  edition  of  the EU Health Award, the European Commission rewarded outstanding 

initiatives  by  cities,  NGOs  and  schools  seeking  to  prevent  and  reduce  obesity  in  children  and 

young people (6-18 years old). Out of the more than 120 proposals received, three were shortlisted 

per category, bringing the total of shortlisted initiatives to nine. Of these, one city, one NGO and 

one  school  were  announced  as  winners  at  the  EU  Health  Award  Ceremony,  which  took  place 

during the annual EU Health Policy Platform meeting hosted by the EU Commissioner for Health 

and Food Safety, Vytenis Andriukaitis, on 17 October 2019 in Brussels66.  

Financial instrument 

PRIZES–  EU  Health  award  for  NGOS, 
city and schools  

Amount committed 
in EUR 

Objective: 
Objectives' description: 

Thematic priority: 

User reference 

-  17.030100 

-  EU 
– 

AWARD 

C2 
HEALTH 
PRIZES 

Chafea – total amount 
committed for prizes 

supportive 

environments 

1 
Promote  health,  prevent  diseases  and 
foster 
for 
healthy  lifestyles  taking  into  account  the 
'health in all policies' principle 
1.1  Cost-effective 
and 
prevention measures in line, in particular, 
with  the  Union  strategies  on  alcohol  and 
nutrition.  
Title 

promotion 

EU HEALTH AWARD PRIZES 

Amount committed 
300 000.00 

300 000.00  

66 https://ec.europa.eu/health/award/previous_editions/2019/preventing_obesity_in_children_en  

52 

 
 
 
 
 
  
 
  
 
  
 
 
 
 
                                                      
7.5 Procurements (service contracts) 

Procurement service contracts were used to purchase a variety of services. Contrary to grants, the 

health programme covers the full cost of procurement actions for the following tasks: 

  evaluation, monitoring of actions and policies, including impact assessment, 

  studies, data analysis and information on health, 

  database development and maintenance, 

  organisation of workshops, trainings, expert panels and coordination groups, 

  scientific and technical assistance, provision of advice and opinions, 

  communication, translations and publications, 

  awareness raising and dissemination of the results, and 

 

information technology applications in support of policies. 

In  2019,  the  Commission  signed  several  service  contracts  and  specific  requests  using  existing 

framework  contracts  (FWC).  Most  of  these  contracts  and  requests  were  for  horizontal  actions, 

such as communication and IT services for the maintenance and functioning of existing IT tools. 

Procurement contracts also covered the services of experts working for the scientific committees, 

for the evaluation of proposals and monitoring studies.  

The amounts per objective and authorising organisation were as follows: 

Health programme 

objective 

Procurement managed by 
DG SANTE (EUR) 

Procurement managed by 

Chafea (EUR) 

1. Health promotion 

2. Health threats 

3.Health systems 

4. Better and safer 

healthcare systems 

5. Horizontal actions 

TOTAL 

396 900,00 

           2 246 793,50 

2 220 000,00 

2 186 565,85 

6 626 708,00 

869 229,70 

14 149 296,55 

845 793,32 

4.478.233,00 

- 

3.618.376,90 

9.339.303,22 

53 

 
 
 
 
The overall public procurement budget implemented by DG SANTE was EUR 9 339 303,22. 
. 
The overall public procurement budget implemented by Chafea was EUR 14 149 296,55.  

In  2019,  CHAFEA  managed  16  procurement  procedures  for  the  acquisition  of  services  (4 

contracts under health promotion, 1 contract under health systems, 4 contracts under health threats 

and 4 under objectives for better and safer health care) and 3 under horizontal actions to support 

the dissemination of the health programme’s results.  

The table below lists all service contracts  signed by Chafea or DG SANTE by objective and by 

priority. 

Financial instrument 

DG SANTE service contracts by objective  Amount committed 

in EUR 

Objectives: 
Objectives' description: 

Thematic priority: 
User reference 

Total 
Total objective  
Objective: 
Objectives' description: 

Thematic priority 

1 
1.  Promote  health,  prevent  diseases  and 
foster  supportive  environments  for  healthy 
lifestyles  taking  into  account  the  'health  in 
all policies' principle 

Title 
1.5 Actions required by, or contributing to, 
the implementation of Union legislation in 
the field of tobacco products ( … ).  
B2 - 17.030100 - STUDY SUPPORTING 
THE COMMISSION REPORT ON 
APPLICATION OF DIRECTIVE 2014/40 
ON TOBACCO PRODUCTS 
B2 - 17.030100 - STUDY SUPPORTING 
THE COMMISSION REPORT ON 
APPLICATION OF DIRECTIVE 2014/40 
ON TOBACCO PRODUCTS 

2. 
Protect Union citizens from serious cross-
border health threats 
2.2.  Support  capacity-building  against  health 
threats  in  Member  States,  including,  where 
appropriate,  cooperation  with  neighbouring 
countries including vaccination 

Amount committed 

1 052.94 

395 847.06 
396 900,00 

C3 - 17.030100 -VACCINATION SUMMIT - 

1 707.90 

54 

 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
SEPT 2019 - BRUSSELS - IGEP - 
LANYARDS AND NOTEBOOKS 
C3 - 17.030100 -VACCINATION SUMMIT - 
SEPT 2019 - BRUSSELS - CONFERENCE 
ASSISTANTS 
C3 - 17.030100 -VACCINATION SUMMIT - 
SEPT 2019 - BRUSSELS - PRODUCTION 
AND INSTALLATION OF BANNER 
C3 - 17.030100 -VACCINATION SUMMIT - 
SEPT 2019 - BRUSSELS - RAPPORTEUR 
C3 - 17.030100 -VACCINATION SUMMIT - 
SEPT 2019 - BRUSSELS - MODERATION 
C3 - 17.030100 -VACCINATION SUMMIT - 
SEPT 2019 - BRUSSELS - IGEP - T-SHIRTS 
C3 - 17.030100 -VACCINATION SUMMIT - 
SEPT 2019 - BRUSSELS - CATERING AND 
OTHER SMALL COSTS - COMPL3 
C3 - 17.030100 -VACCINATION SUMMIT - 
SEPT 2019 - BRUSSELS - CATERING AND 
OTHER SMALL COSTS - COMPL3 
17.030100 -VACCINATION SUMMIT - SEPT 
2019 - BRUSSELS  
17.030100 -VACCINATION SUMMIT - SEPT 
2019 - BRUSSELS  
DIR C - 17.030100 - EUROBAROMETER ON 
VACCINATION ATTITUDES - KANTAR 
DIR C - 17.030100 - CROSS SECTIONAL 
ANALYSIS OF THE EUROBAROMETER ON 
VACCINATION ATTITUDES - DE 
FIGUEIREDO 
DIR C - SI2.823570 - 17.030100 - STATE OF 
VACCINE CONFIDENCE IN THE EU 2020 

2 532.00 

4 081.27 

4 250.00 

3 500.00 

1 435.00 

25 000.00 

1 518.45 

257 493.83 

4 573.67 

299 701.20 

10 000.00 
230 000.00 

845 793.32 

SANTE service contracts by objective 

3 
3. Contribute to innovative, efficient and 
sustainable health systems 
3.6 Implementation of Union legislation in the 
field of medical devices, medicinal products and 
cross-border health care 
Title 
GROW.R.3 -  SI2.803703 - OF 5858 - CC DI/7360 - 
COMPAREX(NL) - E-ORDER 2019-14561 - SPARX 
ENTERPRISE ARCHITECT YEARLY 
MAINTENANCE RENEWAL 2019-2020  
"GROW.R.3 - OF 215 - CC DI/7450 -  SAP 
POWERDESIGNER ENTERPRISE ARCHITECT - 

55 

Amount committed 

443.80 

8 652.00 

Grand total 

Financial 
instrument 
Objective: 
Objectives' 
description: 
Thematic priority: 

User reference 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAP BELGIUM & LUXEMBOURG (BE) - E-
ORDER 2019-16875        
GROW.R.3 -  SI2.805947 - OF 1282 - CC DI/7722 - 
INSIGHT(BE) - E-ORDER 2019-19293 - 
JETBRAINS INTELLIJ IDEA ULTIMATE 2019-
2020 LICENSES YEARLY SUBSCRIPTION 
RENEWAL  
GROW.R.3 - OF 2096 - CC DI/7722 - INSIGHT(BE) - 
E-ORDER 2019-37947 - JETBRAINS INTELLIJ 
IDEA ULTIMATE 
GROW.R.3 - SI2.813257 - CS 3941 - CC DI/7704 - 
EXXEL4EUB-TRASYS(BE) - E-ORDER 2019-7203 
- PATRICIA WIERINCKX / ELISABETE 
MACHADO - PROJECT MANAGER LEVEL 5 
GROW.R.3 - SLG.CMM.2018.52063 + SI2.794693  - 
CS 1170 - CC DI/7704 - EXXEL4EUB-TRASYS(BE) 
- E-ORDER 2018-52063 - PATRICA 
WIERINCKX/ELISABETE MACHADO - PROJECT 
MANAGER LEVEL 5 
GROW.R.3 - SLG.CMM.2019.10968 - CS 3748 - CC 
DI/7700 - XPE GROUP(BE) - E-ORDER 2019-10968 
- EZEKIEL FATUROTI - TECHNOLOGY EXPERT 
LEVEL 4  
GROW.R.3 - SLG.CMM.2019.11609 - CS 2425 - CC 
DI/7702 - BORN4ITB (LU) - E-ORDER 2019-11609 - 
MICHEL AUCLERT - TECHNOLOGY EXPERT 
LEVEL 5 
GROW.R.3 - SLG.CMM.2019.11833 - CS 4291 - CC 
DI/7701 - EURORA NOVA-AHRS(LU) - E-ORDER 
2019-11833 - AUGUSTIN FLORESCU - 
APPLICATION ARCHITECT LEVEL 5  
GROW.R.3 - SLG.CMM.2019.14106 - CS 3528 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-14106 - LUCA VOGNA - APPLICATION 
ARCHITECT LEVEL 5 
GROW.R.3 - SLG.CMM.2019.17238 - CS 4677 - CC 
DI/7700 - XPE GROUP(BE) - E-ORDER 2019-17238 
- BUKOLA OLAWOYIN - TECHNOLOGY EXPERT 
LEVEL 5 
GROW.R.3 - SLG.CMM.2019.17806 - CS 4808 - CC 
DI/7701 - EURORA NOVA-AHRS (LU) - E-ORDER 
2019-17806 - MINHEA ANDREI MAGHETI - 
APPLICATION ARCHITECT LEVEL 4 
GROW.R.3 - SLG.CMM.2019.19186 - CS 4877 - CC 
DI/7701 - EURORA NOVA-AHRS(LU) - E-ORDER 
2019-19186 - SWATHI CHANDRASHEKARAIAH - 
APPLICATION ARCHITECT LEVEL 3 
GROW.R.3 - SLG.CMM.2019.19306 - CS 4873 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-19306 - IONUT TUDOR - ENTERPRISE 
ARCHITECT LEVEL 3 
GROW.R.3 - SLG.CMM.2019.19425 - CS 3453 - CC 
DI/7701 - E-ORDER 2019-19425 - EFTERPI 

56 

1 354.35 

3 179.82 

41 533.20 

6 229.98 

78 038.40 

88 563.60 

43 172.40 

60 177.60 

56 748.00 

79 149.60 

60 507.00 

69 528.80 

50 367.80 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EVANGELIA KOTOUZA - EURORA NOVA-
AHRS(LU) - APPLICATION ARCHITECT LEVEL 5 
GROW.R.3 - SLG.CMM.2019.19707 - CS 4874 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-19707 - TSVETAN YOLOV - APPLICATION 
ARCHITECT LEVEL 3 
GROW.R.3 - SLG.CMM.2019.19730 - CS 4876 - CC 
DI/7702 - BORN4ITB-CRONOS(LU) - E-ORDER 
2019-19730 - ARUNIMA VERMA - APPLICATION 
DEVELOPER LEVEL 4 
GROW.R.3 -  SLG.CMM.2019.20827 - CS 5101 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-20827 - TOM LARMINIER - ENTERPRISE 
ARCHITECT LEVEL 5 
GROW.R.3 - SLG.CMM.2019.20839 - CS 5102 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-20839 - OMAR EL YAHYAOUI - 
APPLICATION ARCHITECT LEVEL 5  
GROW.R.3 - SLG.CMM.2019.23386 - CS 3451 - CC 
DI/7701 - E-ORDER 2019-23386 - BRUNO PAIVA - 
EURORA NOVA-AHRS(LU) - APPLICATION 
ARCHITECT LEVEL 2 
GROW.R.3 - SLG.CMM.2019.23862 - CS 5393 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-23862 - REMO MORO - APPLICATION 
ARCHITECT LEVEL 4 
GROW.R.3 - SLG.CMM.2019.25840 - CS 5579 - CC 
DI/7702 - BORN4ITB-CRONOS(LU) - E-ORDER 
2019-25840 - KUMAR PRASHANT - 
APPLICATION ARCHITECT LEVEL 3 
GROW.R.3 - SLG.CMM.2019.26070 - CS 5582 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-26070 - LAURA FERNANDEZ Y GARCIA - 
UX UI SPECIALIST LEVEL 4 
GROW.R.3 - SLG.CMM.2019.26992 - CS 5781 - CC 
DI/7701 - EURORA NOVA-AHRS(LU) - E-ORDER 
2019-26992 - GIUSEPPE PERRICONE - 
TECHNOLOGY EXPERT LEVEL 3  
GROW.R.3 - CS 5800 - CC DI/7704 - EXXEL4EUB-
TRASYS(BE) - E-ORDER 2019-27279 - TSVETAN 
YOLOV - APPLICATION ARCHITECT LEVEL 3 - 
56.887,20 EUR 
GROW.R.3 - SLG.CMM.2019.27359 - CS 5784 - CC 
DI/7712 - EXXEL4EUS-UNISYS(BE) - E-ORDER 
2019-27359 - ORLANDO JAIME DOS SANTOS 
SEIXAL LARANJO - SERVICE DESK AGENT 
LEVEL 3 
GROW.R.3 - SLG.CMM.2019.27377 - CS 5785 - CC 
DI/7713 - TEIDE-EVERIS(BE) - E-ORDER 2019-
27377 - SAMIRA BEN LARBI - DATABASE 
APPLICATION ADMINISTRATOR LEVEL 3 

GROW.R.3 - SLG.CMM.2019.27660 - CS 5581 - CC 

57 

50 566.40 

53 580.00 

75 222.00 

45 133.20 

55 552.00 

82 714.80 

43 424.50 

102 821.40 

9 811.26 

56 887.20 

3 459.00 

4 380.80 
131 638.50 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-27660 - ASHLEY COUPLAND - 
APPLICATION ARCHITECT LEVEL 5  

GROW.R.3 - SLG.CMM.2019.27949 - CS 5783 - CC 
DI/7713 - TEIDE-EVERIS(BE) - E-ORDER 2019-
27949 - JEAN-NOEL CLAES - SUPPORT 
MANAGER LEVEL 3 

GROW.R.3 - SLG.CMM.2019.28064 - CS 5798 - CC 
DI/7701 - EURORA NOVA-AHRS(LU) - E-ORDER 
2019-28064 - MAX KUDRENKO - APPLICATION 
ARCHITECT LEVEL 5 

GROW.R.3 - CS 5779 - CC DI/7704 - EXXEL4EUB-
TRASYS(BE) - E-ORDER 2019-28103 - WILLIAM 
PROCTER - QUALITY / ASSURANCE MANAGER  

GROW.R.3 - SLG.CMM.2019.28230 - CS 5866 - CC 
DI/7702 - BORN4ITB-CRONOS(LU) - E-ORDER 
2019-28230 - BRENDAN DOHERTY - 
APPLICATION ARCHITECT LEVEL 5 
GROW.R.3 - SLG.CMM.2019.28252 - CS 5802 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-28252 - DENISA VLAICU - PROJECT 
MANAGER LEVEL 5  
GROW.R.3 - SLG.CMM.2019.28407 - CS 5795 - CC 
DI/7700 - XPE GROUP(BE) - E-ORDER 2019-28407 
- BUKOLA OLAWOYIN - TECHNOLOGY EXPERT 
LEVEL 5  
GROW.R.3 - SLG.CMM.2019.29269 - CS 5799 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-29269 - DUNG TRUONG - TECHNOLOGY 
EXPERT LEVEL 5 
GROW.R.3 - SLG.CMM.2019.29370 - CS 5924 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-29370 - LUCA VOGNA - APPLICATION 
ARCHITECT LEVEL 5 
GROW.R.3 - SLG.CMM.2019.29828 - CS 5782 - CC 
DI/7713 - TEIDE-EVERIS(BE) - E-ORDER 2019-
29828 - JOSE RAMOS - IS SUPPORT MANAGER 
LEVEL 4 
GROW.R.3 - SLG.CMM.2019.30140 - CS 5922 - CC 
DI/7700 - XPE GROUP(BE) - E-ORDER 2019-30140 
- MARTINE GUEBEL- PROJECT MANAGER 
LEVEL 5 
GROW.R.3 - SLG.CMM.2019.30498 - CS 5993 - CC 
DI/7701 - EURORA NOVA-AHRS(LU) - E-ORDER 
2019-30498 - EWA OLOW - ENTREPRISE 
ARCHITECT LEVEL 5 
GROW.R.3 - SLG.CMM.2019.31116 - CS 5867 - CC 
DI/7701 - EURORA NOVA-AHRS(LU) - E-ORDER 
2019-31116 - AUGUSTIN FLORESCU - 

58 

8 785.98 

64 758.60 

5 247.50 

88 563.60 

10 383.30 

70 935.00 

4 137.21 

90 266.40 

3 980.62 

7 093.50 

13 190.80 

16 909.19 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPLICATION ARCHITECT LEVEL 5  

GROW.R.3 - SLG.CMM.2019.35865 - CS 6269 - CC 
DI/7701 - E-ORDER 2019-35865 - EFTERPI 
EVANGELIA KOTOUZA - EURORA NOVA-
AHRS(LU) - APPLICATION ARCHITECT LEVEL 5 
GROW.R.3 - - CS 6731 - CC DI/7702 - BORN4ITB-
CRONOS(LU) - E-ORDER 2019-38759 - MICHEL 
AUCLERT - TECHNOLOGY EXPERT - LEVEL 5 - 
73.803,00 EUR 
GROW.R.3 - SLG.CMM.2019.40276 - CS 6729 - CC 
DI/7701 - EURORA NOVA-AHRS(LU) - E-ORDER 
2019-40276 - MARIANA NASCIMENTO - 
BUSINESS ANALYST LEVEL 5 
GROW.R.3 - CS 6732 - CC DI/7701 - EURORA 
NOVA-AHRS (LU) - E-ORDER 2019-42295 - 
MINHEA ANDREI MAGHETI - APPLICATION 
ARCHITECT LEVEL 4 - 65.958,00 EUR 
GROW.R.3 - CS 3457 - CC DI/7702 - BORN4ITB-
CRONOS(LU) - E-ORDER 2019-42780 - DIMITAR 
MARINOV - TECHNOLOGY EXPERT LEVEL 5 - 
73.803,00 EUR 
GROW.R.3 - CS 6914 - CC DI/7700 - XPE 
GROUP(BE) - E-ORDER 2019-42889 - EZEKIEL 
FATUROTI - TECHNOLOGY EXPERT LEVEL 4 -  

GROW.R.3 - SLG.CMM.2019.44767 - CS 7369 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-44767 - TOM LARMINIER - ENTERPRISE 
ARCHITECT - LEVEL 5 
GROW.R.3 - CS 7039 - CC DI/7704 - EXXEL4EUB-
TRASYS(BE) - E-ORDER 2019-44915 - OMAR EL 
YAHYAOUI - APPLICATION ARCHITECT - 
LEVEL 5 - 22.566,60 EUR 
GROW.R.3 - SLG.CMM.2019.45916 - CS 7244 - CC 
DI/7701 - E-ORDER 2019-45916 - BRUNO PAIVA - 
EURORA NOVA-AHRS(LU) - APPLICATION 
ARCHITECT LEVEL 2 
GROW.R.3 - SLG.CMM.2019.47258 - CS 7491 - CC 
DI/7701 - EURORA NOVA-AHRS(LU) - E-ORDER 
2019-47258 - SWATHI CHANDRASHEKARAIAH - 
APPLICATION ARCHITECT LEVEL 4 
GROW.R.3 -  SLG.CMM.2019.48551 - CS 7487 - CC 
DI/7702 - BORN4ITB-CRONOS(LU) - E-ORDER 
2019-48551 - KUMAR PRASHANT - 
APPLICATION ARCHITECT LEVEL 4 
GROW.R.3 - SLG.CMM.2019.48777 - CS 7490 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-48777 - IONUT TUDOR - ENTERPRISE 
ARCHITECT LEVEL 3 
GROW.R.3 - SLG.CMM.2019.48940 - CS 7492 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2019-48940 - REMO MORO - APPLICATION 

59 

100 735.60 

73 803.00 

11 093.00 

65 958.00 

73 803.00 

65 032.00 

56 416.50 

22 566.60 

77 772.80 

98 937.00 

108 222.40 

103 393.50 

105 310.80 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ARCHITECT LEVEL 5 

GROW.R.3 - SLG.CMM.2019.52566 - CS 8179 - CC 
DI/7701 - EURORA NOVA-AHRS(LU) - E-ORDER 
2019-52566 - MAX KUDRENKO - APPLICATION 
ARCHITECT LEVEL 5  
GROW.R.3 - SLG.CMM.2019.52783 - CS 7494 - CC 
DI/7702 - BORN4ITB-CRONOS(LU) - E-ORDER 
2019-52783 - ARUNIMA VERMA - APPLICATION 
DEVELOPER LEVEL 4 
GROW.R.3 - SLG.CMM.2019.54799 - CS 8514 - CC 
DI/7702 - BORN4ITB-CRONOS(LU) - E-ORDER 
2019-54799 - ARUNIMA VERMA - APPLICATION 
DEVELOPER LEVEL 5  
GROW.R.3 - SLG.CMM.2019.56013 - CS 8180 - CC 
DI/7700 - XPE GROUP(BE) - E-ORDER 2019-56013 
- BUKOLA OLAWOYIN - TECHNOLOGY EXPERT 
LEVEL 5  
GROW.R.3 - SLG.CMM.2019.9818 + SI2.801977 - 
CS 3001 - CC DI/7704 - EXXEL4EUB-TRASYS(BE) 
- E-ORDER 2019-9818 - DUNG TRUONG - 
TECHNOLOGY EXPERT LEVEL 5 
UNIT E5 - 17.030100 - EXPERT MISSION COSTS 
RE VICH MEETINGS 2019 - COMPL 

B5 - SANTE/2019/B5/004 - 17.030100 - 
STAKEHOLDER EVENT ON EVALUATION OF 
ORPHAN AND PAEDIATRIC REGULATIONS – 
COMPL 

B5 - 17.030100 - STAKEHOLDER EVENT ON 
EVALUATION OF ORPHAN AND PAEDIATRIC 
REGULATIONS – AMEX 

UNIT B3 - 17.030100 - SERVICES FOR 
STAKEHOLDER EVENT ON EVALUATION OF 
ORPHAN AND PAEDIATRIC LEGISLATION 

C2 - 17.030100/19/801516 - SCIENTIFIC 
COMMITTEES AND PROVISION OF 
TARGUETED RISK ASSESSMENT IN CASE OF A 
CHEMICAL AND ENVIRONMENTAL INCIDENT 
OF CROSS BORDER RELEVANCE - COMPL 

UNIT B1 - 17.030100 - EXPERT PANEL ON 
INVESTING IN HEALTH - SPECIAL 
INDEMNITIES FOR EXPERTS - COMPL 

B5 - SI2.813150 - ICH AND  IPPR MEMBERSHIP 
FEE FOR 2020 -  

60 

88 015.20 

18 186.40 

39 529.60 

50 614.20 

45 133.20 

30 000.00 

32 408.46 

4 723.10 

6 000.00 

420 000.00 

300 000.00 

260 000.00 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
GROW/D4 - MEETINGS OF THE MEDICAL 
DEVICES COORDINATION GROUP (MDCG)  
COVERING TRAVEL EXPENSES OF 
PARTICIPANTS - 2019 

DIR F - 17.0301 - REIMBURSEMENT OF EXPERTS 
FOR JOINT ASSESSMENTS ON MEDICAL 
DEVICES – COMPL 

B5 - 19 - SI2.803848 - JOINT AUDIT PROGRAMME 
ON GOOD MANUFACTURING PRACTICE 

ICH MEETINGS - REIMBURSEMENT OF 
EXPERTS 

B1 - SI2.804177 - SANTE2019 /B1/001 - 
ORGANISATION OF 6 HEAIRINGS OF THE 
EXPERT PANEL OF EFFECTIVE WAYS OF 
INVESTING IN HEALTH  

UNIT E5 - 17.030100 - EXPERT MISSION COSTS 
RE VICH MEETINGS 2019 - COMPL 

B1 - 17.030100 - EXPERT PANEL ON EFFECTIVE 
WAYS OF INVESTING IN HEALTH 
CONFERENCE ON 08/11/2019- AMEX 

ICH AMSTERDAM 01 TO 06 JUNE 

CO-DEL DG GROW (SANTE) - MEDICAL 
DEVICES 

Thematic priority:  3.7  4.6  Health  information  and  knowledge  system 
including  support  to  the  Scientific  Committees  set 
up 
in  accordance  with  Commission  Decision 
2008/721/EC 
B1 - 17.030100/19/SI2.812477 - ACCESSIBILITY OF 
PHARMACEUTICAL 
AND 
PHARMACEUTILCAL 
SUSTAINABILITY  OF 
SPENDING 

CARE 

240 000.00 

213 000.00 

85000 

80000 

79200 

30000 

28654.3 

6897.74 

5756.55 

140 162.00  

ICH SINGAPORE 16 TO 20 NOVEMBER 

80 000.00 

SANTE -  IT SPECIFIC CONTRACTS - EUDAMED 
2020 - BL 17.030100 

200,559.09 

124 226,80 

-  SI2.823486 

B5 
-  STUDY 
SUPPPORTING  THE  IMPACT  ASSESSMENT  OF 

17.030100 

- 

61 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE  REVISION  OF  THE  EMA  FEE  SYSTEM  - 
FDIX2 

SC 381 - DATA PROTECTION AND IT SECURITY 
COMPLIANCE  OF  THE  CPMS  IN  THE  CONTEXT 
OF  CONSULTATIONS  BY  THE  ERN 
(OF 
2020.31317) - MOD FDI 

189 736, 50 

- 

17.030100 

-  SI2.823486 

B5 
-  STUDY 
SUPPPORTING  THE  IMPACT  ASSESSMENT  OF 
THE  REVISION  OF  THE  EMA  FEE  SYSTEM  - 
FDIX2 

- 

17.030100 

-  SI2.823486 

B5 
-  STUDY 
SUPPPORTING  THE  IMPACT  ASSESSMENT  OF 
THE  REVISION  OF  THE  EMA  FEE  SYSTEM  - 
FDIX2 

- 

17.030100 

-  SI2.823486 

-  STUDY 
B5 
SUPPPORTING  THE  IMPACT  ASSESSMENT  OF 
THE  REVISION  OF  THE  EMA  FEE  SYSTEM  - 
FDIX2 

Grand total 
Objective: 
Objectives' 
description: 
Thematic priority: 
User reference 

B3  -  17.030100  -  STUDY  ON  CROSS  BORDER 
HEALTHCARE  IN  THE  EU  -E&Y  -  AM1+2  FOR 
EXTENSION 
ICH USA 30 OCT TO 04 NOV 
ICH TOKYO 24 AU 31 MARS  

5 
5.  IT  /  dissemination  (Horizontal  action  related  to  all 
objectives)  
horizontal ICT / dissemination 
Title 
CC,  CS896,  2019-58598,  CANCOM  ON  LINE 
GMBH*  -  2S-GEN10-AM12              (cid:13)STANDARD  2 
SOCKET  RACKABLE  DL380  GEN10  -  V2  - 
COMPUTE  PLATFORM  -  DEDICATED  SERVER  - 
PURCHASE 

62 

36,447.25 

80,367.45 

90,000.00 

635,122.00 

2,394.32 
3,100.00 
4.478.233,00 

Amount committed 

199,93 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OF 2831 - JETBRAINS PHP STORM LICENSE  

262,10 

SC  13593  -  EM  -  USER  DOCUMENTATION  AND 
TRAINING - LATE INTERESTS 

281,70 

2852 

OF 
MAINTENACEBY MADCAP 

FLARE 

- 

FLOATING 

BRONZE 

400,00 

CC07460,  CS000206,  2019-24291,  DIMENSION  DATA 
BELGIUM   
EORDER FWC DI/07460 (OASIS II) DIMENSION DATA 
BELGIUM   
UNIX  BASIC  SERVICES  -  APPLICATION  HOUSING  - 
BASIC MODE SERVICE 

388 329,49 

5849 

OF 
EQUIPMENT/LICENSES 

- 

MAINTENANCE 

OF 

IT 

650,19 

SANTE/2019/02/047 
FOR VACCINATION 

-  PROMOTIONAL  MATERIAL 

837,00 

C2 - 17.030100 - EU HEALTH AWARD - PRIZES 

300 000,00 

C2  - 17.030100 - EU  HEALTH AWARD AND HEALTH 
POLICY PLATFORM MEETINGS - 2019 - TECHNICAL 
EQUIPMENT VENUE 

1.189,70 

OF 6010 - ELA VMWARE YEAR 3 (CD) 

OF 6010 - ELA VMWARE YEAR 3 (CD) 

OF 6010 - ELA VMWARE YEAR 3 (CD) 

1.200,00 

1.200,00 

1.200,00 

CC07720, 
BRUSSELS            

CS1005525, 

2019-33827, 

BECHTLE 

1.211,06 

FWC  DI/07720  -  SOFTWARE  FOR  INNOVATION, 
DIVERSITY AND EVOLUTION II (SIDE II) - BECHTLE 
BRUSSELS            

ARIS  -  ELA  SOFTWARE  AG  MI  IMPLEMENTATION 
OF ELA SOFTWARE AG - REF ELA-SOFTWAREAG-1 
-  

C2  -  17.030100  -  ASSISTANCE  EU  HEALTH  POLICY 
PLATFORM  AND  EU  HEALTH  AWARD 
- 
NOVACOMM-AUSY 

189.500,00 

SC 457 - DG SANTE WEBSITES MANAGEMENT 

176.400,00 

63 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OF  1546  -  SOFTWARE  PRODUCTS,  MAINTENANCE, 
SUPPORT 

1.450,70 

OF 2294 -  LANCRYPT LICENSE + MAINTENANCE 

1.462,41 

SC  2567  -  FD  -  WEB  OPERATIONS  MANAGER  FOR 
SANTE POLICIES (AV 1) 

1.500,00 

CO-DEL DG SANTE- 2019 - PUBLIC HEALTH DIR B, C 
+ UNIT 02       

130.100,00 

OF 
PRODUCTS,MAINTENANCE AND SUPPORT 

1007787 

- 

SOFTWARE 

C2  - 17.030100 - EU  HEALTH AWARD AND HEALTH 
POLICY 
- 
TRANSPORT/ACCOMMODATION/VENUE/CATERIN
G 

PLATFORM  MEETINGS 

2019 

- 

1.640,67 

110813,3 

OF  5854 
SOFTWARE TOAD 

-  MAINTENANCE  RENEWAL  QUEST 

1.799,40 

CC,  CS349,  2019-57171,  CANCOM  ON  LINE  GMBH*       

1.888,40 

ACER  B276HUL  27  INCHES  DISPLAY  SCREEN  - 
OTHER (ADDITIONAL SCREENS, SPEC; MICE, ...) 

CC,  CS22,  2019-56623,  TELECOM  ITALIA  SPARKLE 
SPA       

2.276,90 

 SERVICES - PUBLIC CLOUD PAAS - SUITE AU CS 20 
- CLOUD_COSTS 

SC  1560  -    AG  -  APPLICATION  ARCHITECT  FOR  BI 
PROJECTS (OF 2019.17334) 

2.369,28 

CC, 
PRICEWATERHOUSECOOPERS 

CS000352, 

2019-55175, 
SERVICES  

EU 

100.000,00 

EORDER   

EXTENSION  OF  EU  SEND  COMMUNICATION  AND 
ONBOARDING 
STAKEHOLDERS_ 
MANAGEMENT 

D3 

- 

64 

 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
CC07490,  CS000179  AV1,  2019-50762,  SOPRA  STERIA 
BENELUX         

96.336,54 

FWC 

DI/07490 

MSP 

II         

DESIGN  SERVICES  -  STARTDATE:  01/12/2019  - 
ENDATE: 
- 
-  MODE 
31/03/2020 
SUPPORTING SERVICE DEVELOPME 

SERVICE 

OF 1396 - RENEWAL MAINTENANCE LICENSES 

2.752,99 

SC  1052  -  PS  -  PROJECT  MANAGER  FOR  HEALTH 
PROJECTS - AV 2 

3.000,00 

SC 4492 - RR - APPLICATION ARCHITECT  

94.694,60 

02 - PROMOTION MATERIAL OF SANTE/2019/02/036 

3.163,00 

02  -  SOCIAL  MEDIA  PILOT  -  PO-2016-12-A2-160-
SANTE - MOD FDI 

92.900,00 

02  -  SC  509  -  WEB  MAINTENANCE  AND  CRAWLER 
WEBSITES DG SANTE 

3.313,33 

02  -  SC    458  -  WEB  VISUAL  DESIGNERS  FOR  DG 
SANTE 

84.000,00 

CC,  CS1007320,  2019-57152,  BECHTLE  BRUSSELS       
MOBILEIRON  THREAT  DEFENSE  RENEWAL  PER 
INTRUSION  PREVENTION 
USER  RENEWAL 
INTO 
SYSTEM 

- 
INTEGRATED 

THE        

3.550,20 

MOBILEIRON  CLIENT  TO  DEFEND  AGAINST 
DEVICE,  NETWORK,  AND  APPLICATION  BASED 
CYBER-ATTACK 

FWC  DI/07753 

2019-52326,  BECHTLE 
CC07753,  CS7753-6972, 
BRUSSELS 
-  DATACENTRE 
INFRASTRUCTURE  SOLUTIONS  (DIS)  -  BECHTLE 
BRUSSELS  DREAN  OLIVIER  -  PREST  REGIE  -  SUPP 
SYST CIS - ITIL,PROCESSES (TECH ADM ITIL) 

3.835,00 

SC  5065  -  EM  -  PROJECT  MANAGER  FOR  FOOD 
SAFETY  AND  HEALTH  PROJECTS  -  INCREASE 
AMOUNT/ NEW END DATE 

76.222,00 

SC  5835  -  MIB  -  BUSINESS  ANALYST  FOR    PUBLIC 
HEALTH PROJECTS - MOD MT 

70.079,30 

65 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CC07490,  CS000163,  2019-26886,  SOPRA  STERIA 
BENELUX       
FWC  DI/07490  MSP  II            BASIC  SERVICES  -  CORE 
SERVICES 
(UNTIL 
31/10/2019)  -  MODE  SERVICE  -  BASIC  SERVICES 
CORE 

-  STARTDATE: 

01/07/2019 

65.665,97 

SC 3016 - RD - PROJECT MANAGER FOR EUROPEAN 
MEDICINAL PRODUCTS (OF 2019.20972) 

55.377,60 

SC  5548  -  DB  - 
EUROPEAN MEDICINAL PRODUCTS (EMP) 

  TECHNOLOGY  EXPERT  FOR 

4.314,60 

SC 1479 - LM - SUPPORT MANAGER (GRANGE) FOR 
FOOD  AND  HEALTH  POLICIES  (RE-COMMITMENT 
SI2.801694) 

54.236,80 

 SC 5577  - CB - IS TESTER FOR FOOD POLICIES (CD)  53.867,20 

CC,  CS348,  2019-57169,  CANCOM  ON  LINE  GMBH*      
ACER  B276HUL  27  INCHES  DISPLAY  SCREEN  - 
OTHER (ADDITIONAL SCREENS, SPEC; MICE, ...) 

4.721,00 

CC07490,  CS000179  AV1,  2019-50762,  SOPRA  STERIA 
BENELUX         
FWC 
DESIGN  SERVICES  -  STARTDATE:  01/12/2019  - 
- 
-  MODE 
31/03/2020 
ENDATE: 
SUPPORTING SERVICE DEVELOPME 

SERVICE 

DI/07490 

MSP 

II         

51.815,70 

CC07370, 
ASSOCIATION 

CS9820, 

2019-53206, 

COMLIN 

4.993,20 

MOMENTANEE   

FRAMEWORK  CONTRACT  DI/07370-00  (NESTOR  III) 
- 

COMLIN   

PAIR  8  -  DISKS  REORGANISATION  -  PROJETS  - 
PROCEDURES - ETUDES - AMENAGT IT INFRASTR 

C2  - 17.030100 - EU  HEALTH AWARD AND HEALTH 
POLICY PLATFORM MEETINGS - 2019  

5.000,00 

SC  5746  -  CT  -  SUPPORT  MANAGER  FOR  PUBLIC 
HEALTH AND FOOD POLICIES 

5.000,00 

SC  5769  -  EM  -  SUPPORT  MANAGER  FOR  PUBLIC 
HEALTH AND FOOD POLICIES 

5.000,00 

SC  5769  -  EM  -  SUPPORT  MANAGER  FOR  PUBLIC  5.000,00 

66 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HEALTH AND FOOD POLICIES 

SC 4787 - RB - APPLICATION ARCHITECT FOR FOOD 
SAFETY  AND  PUBLIC  HEALTH  PROJECTS  (OF 
2019.28885) 

5.000,00 

SC  8061-  CL-  SUPPORT  MANAGER  FOR  SANTE 
POLICIES 

5.000,00 

CC,  CS2038,  2019-54312,  BECHTLE  BRUSSELS    

50.893,00 

EORDER     

LENOVO THINKPAD L390 HEPM - QUK - LAPTOPS 

SC  5855  -  CB  -  APPLICATION  ARCHITECT  FOR 
PUBLIC HEALTH AND FOOD SAFETY PROJECTS (OF 
2019.28889) 

5.491,20 

CO-DEL DG GROW (SANTE) - MEDICAL DEVICES       5.756,55 

OF  929  -  RENEWAL  SUBSCRIPTION  TO  LICENSES 
AND SOFTWARES 

6.000,00 

A4  -  SC  1258  -  MBM  -  TECHNOLOGY  EXPERT  FOR  
FOOD AND FED AND PUBLIC HEALTH OPEN DATA 
PROJECTS (OF 2019-4658) 

50.690,24 

CC07460,  CS000241,  2019-49786,  NTT  BELGIUM       

6.068,49 

EORDER  FWC  DI/07460  (OASIS  II)  -  DIMENSION 
DATA 

BELGIUM       

DIAS  FABIO  -  PROFILE:  ARCHITECT  (AR)  -  (LEVEL 
OF EXPERTISE:NORMAL) - APPLICATION HOUSING 
- CLOD MANAGEMENT 

SC  5548  -  DB  - 
EUROPEAN MEDICINAL PRODUCTS (EMP) 

  TECHNOLOGY  EXPERT  FOR 

49.927,80 

CC07720, 
BRUSSELS            

CS1005525, 

2019-33827, 

BECHTLE 

6.554,94 

FWC  DI/07720  -  SOFTWARE  FOR  INNOVATION, 
DIVERSITY AND EVOLUTION II (SIDE II) - BECHTLE 
BRUSSELS            

ARIS  -  ELA  SOFTWARE  AG  MI  IMPLEMENTATION 
OF ELA SOFTWARE AG - REF ELA-SOFTWAREAG-1 

67 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-  

C2  - 17.030100 - EU  HEALTH AWARD AND HEALTH 
POLICY 
- 
INTERPRETATION BOOTHS 

PLATFORM  MEETINGS 

2019 

- 

6.886,00 

CC07706,  CS005396, 

2019-24015,  C-DEV 

SA   

47.907,20 

EORDER  FWC  DI/07706,  FRAMEWORK  CONTRACT, 
DIGIT-TM, 

CONTRACTOR   

LOT 

2ND 

2, 

MANDELAIRE  ARNAUD  -  PROFILE:  TECHNOLOGY 
EXPERT  (TEX)  -  (LEVEL  OF  EXPERTISE:LEVEL  5)  - 
CORPORATE ACTIVE DIRECTORY TIME&MEANS 

SC  8057  -  RD  -  PROJECT  MANAGER  FOR  PUBLIC 
HEALTH AND FOOD SAFETY PROJECTS 

45.685,40 

SC  4775  -  JDA  -  CONFIGURATION/DEPLOYMENT 
MANAGEREXPERTISE:LEVEL 3) -  

7.245,00 

SC  4784  -  MC  -  DATABASE  DEVELOPER  FOR 
SHAREPOINT  

7.470,00 

SC  4610  -LV-  SUPPORT  MANAGER  FOR  HEALTH, 
FOOD  AND  FEED  -    AV1  BUDGET  DECREASE  -
CHANGE REQUEST TYPE TM->PTM  

8.000,00 

SC  4776  -  FD  -  WEB  OPERATIONS  MANAGER  FOR 
SANTE POLICIES  

45.000,00 

02  -  PO-2016-12-A2-203-SANTE  -  SOCIAL  MEDIA 
BOOSTING DG SANTE 

41.970,00 

CC,  CS886,  2019-58612,  CANCOM  ON  LINE  GMBH*       
A2S-8SFF_AM12        

8.910,00 

ADVANCED 2 SOCKETS RACKABLE DL380-GEN10 - 
V2 
- 
DEDICATED SERVER - PURCHASE 

-  COMPUTE  PLATFORM 

(64GB  DIMMS) 

SANTE/2019/02/062 
VACCINATION 

- 

INTERVIEWS 

ON 

39.540,00 

SC  1169 
ANALYST 

-  SECURITY  OPERATIONS  CENTRE 
  FOR  HEALTH  AND  FOOD  SAFETY 

9.975,45 

68 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROJECTS 

02  -  SANTE/2019/02/017  -  PRODUCTION  OF  ERN 
BROCHURE 
E-PRESCRIPTION/PATIENT 
SUMMARY ELECTRONIC FLYER  - MOD FDI 

AND 

39.480,00 

SC 4787 - RB - APPLICATION ARCHITECT FOR FOOD 
SAFETY  AND  PUBLIC  HEALTH  PROJECTS  (OF 
2019.28885) 

10.000,00 

SC  1044  DI  7701    UX  /  UI    INBRUSSELS  FOR 
TOBACCO INGREDIENTS - AV1 BUDGET DECREASE 
- CHANGE REQUEST TYPE PTM->TM 

10.000,00 

CC, 

CS000252, 

2019-54885,  NTT 

BELGIUM   

10.025,64 

EORDER    

YOHAN 

FRACHISSE 
SENIOR 
TECHNICAL  ADMINISTRATOR  (STAD)  -  (LEVEL  OF 
EXPERTISE:NORMAL)  -  APPLICATION  HOUSING  - 
BASIC MODE SERVICE 

PROFILE: 

- 

SC 1598 - SV - UX/UI SPECIALIST FOR HEALTH AND 
FOOD PROJECTS - MOD MT (PTM->TM) 

36.917,00 

SC 3041 - AL - APPLICATION ARCHITECT FOR UMP, 
PUBLIC  HEALTH  AND  FOOD  SAFETY  PROJECTS 
(CD) 

10.902,50 

SC  5835  -  MIB  -  BUSINESS  ANALYST  FOR    PUBLIC 
HEALTH PROJECTS - MOD MT 

36.458,10 

SC  7848  - 
  MM  -  APPLICATION  ARCHITECT 
SHAREPOINT  FOR  PUBLIC  HEALTH  &  FOOD 
SAFETY PROJECTS 

12.232,00 

SC  4610  -LV-  SUPPORT  MANAGER  FOR  HEALTH, 
FOOD  AND  FEED  -    AV1  BUDGET  DECREASE  -
CHANGE REQUEST TYPE TM->PTM  

12.262,10 

SC 5747 - JPB - USER SUPPORT SERVICES  

SC  5854  -  AL  -  APPLICATION  ARCHITECT  FOR 
HEALTH AND FOOD SAFETY PROJECTS 

CC,  CS008459,  2019-54195,  EUROPEAN  DYNAMICS 
LUXEMBOURG 

SA*ED       

12.696,00 

12.928,80 

35.223,10 

EORDER        

69 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PADHI  SANGHAMITRA  -  PROFILE:  TECHNOLOGY 
EXPERT  (TEX)  -  (LEVEL  OF  EXPERTISE:LEVEL  2)  - 
CC_DEVELOPMENT_O* 

C2  - 17.030100 - EU  HEALTH AWARD AND HEALTH 
POLICY PLATFORM MEETINGS - 2019 - TECHNICAL 
EQUIPMENT VENUE 

13.776,17 

-  GLOBAL  VACCINATION  SUMMIT 

02 
SESSION PO SANTE/2019/02/041 

INFO 

14.095,00 

SC 3846 - RB - APPLICATION ARCHITECT FOR FOOD 
SAFETY  AND  PUBLIC  HEALTH  PROJECTS  (OF 
2019.10467) 

15.000,00 

SC  4784  -  MC  -  DATABASE  DEVELOPER  FOR 
SHAREPOINT  

15.000,00 

SC  4784  -  MC  -  DATABASE  DEVELOPER  FOR 
SHAREPOINT  

15.000,00 

SC  1044  DI  7701    UX  /  UI    INBRUSSELS  FOR 
TOBACCO INGREDIENTS - AV1 BUDGET DECREASE 
- CHANGE REQUEST TYPE PTM->TM 

15.000,00 

SC  5574  -  VC  -  APPLICATION  ARCHITECT  FOR 
HEALTH AND FOOD PROJECTS 

16.000,00 

SC  5574  -  VC  -  APPLICATION  ARCHITECT  FOR 
HEALTH AND FOOD PROJECTS 

16.000,00 

OF  896  -  RENEWAL  SUBSCRIPTION  TO  KIUWAN  1 
YEAR 

16.844,76 

SC 5767 - MF - PROJECT MANAGER FOR FOOD AND 
HEALTH PROJECTS 

35.000,00 

SC  7455  -  PS  -  PROJECT  MANAGER  FOR  PUBLIC 
HEALTH PROJECTS  (OF 2019.45144) 

17.278,30 

SC  1560  -    AG  -  APPLICATION  ARCHITECT  FOR  BI 
PROJECTS (OF 2019.17334) 

33.453,34 

SC  4775  -  JDA  -  CONFIGURATION/DEPLOYMENT 
MANAGEREXPERTISE:LEVEL 3) -  

20.000,00 

SC  5749  -  CF  -  PROJECT  MANAGER  FOR  FOOD 
SAFETY AND HEALTH PROJECTS 

20.000,00 

70 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SC  4776  -  FD  -  WEB  OPERATIONS  MANAGER  FOR 
SANTE POLICIES  

21.405,60 

CC07370, 
ASSOCIATION 

CS9722, 

2019-23315, 

COMLIN 

21.500,00 

MOMENTANEE*       

NEW  ANNEX  I  -  CLAUSSE  DIDIER  -  PREST  REGIE  - 
SUPP  SYST  CIS  -  STORAGE(SYS  ENGIN  OPER, 
ARCH) 

SC  5855  -  CB  -  APPLICATION  ARCHITECT  FOR 
PUBLIC HEALTH AND FOOD SAFETY PROJECTS (OF 
2019.28889) 

22.000,00 

SC  5855  -  CB  -  APPLICATION  ARCHITECT  FOR 
PUBLIC HEALTH AND FOOD SAFETY PROJECTS (OF 
2019.28889) 

22.000,00 

SANTE/2019/02/044  -  SOCIAL  MEDIA  VIDEOS  ON 
STATE OF HEALTH 

22.460,00 

SC  1169 
ANALYST 
PROJECTS 

-  SECURITY  OPERATIONS  CENTRE 
  FOR  HEALTH  AND  FOOD  SAFETY 

32.246,70 

CC07460,  CS000239,  2019-49775,  NTT  BELGIUM       

23.916,99 

EORDER  FWC  DI/07460  (OASIS  II)  -  DIMENSION 
DATA 

BELGIUM       

ALMEIDA  TOMÉ  -  PROFILE:  ARCHITECT  (AR)  - 
(LEVEL  OF  EXPERTISE:NORMAL)  -  CORPORATE 
ACTIVE DIRECTORY TIME&MEANS 

SC  5850  -  RB  -  TECHNOLOGY  EXPERT  FOR  E-
HEALTH,  PUBLIC  HEALTH  AND  FOOD  SAFETY 
PROJECTS 

24.402,90 

CC07722, CS2306, 2019-49069, INSIGHT DIRECT USA, 
INC.   

30.164,72 

FWC 

DI/07722 

(SIDE 

II)- 

INSIGHT   

CONSULTANCY KUBERNETES AS A SERVICE BETA 
-  SERVICE  -  DATA  CENTRE  PRODUCT,  RED  HAT 
SUPPORT AND RC 

SC  4776  -  FD  -  WEB  OPERATIONS  MANAGER  FOR 
SANTE POLICIES  

25.000,00 

71 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SC  3517  - 
  MM  -  APPLICATION  ARCHITECT 
SHAREPOINT  FOR  PUBLIC  HEALTH  &  FOOD 
SAFETY PROJECTS 

26.000,00 

SC 3846 - RB - APPLICATION ARCHITECT FOR FOOD 
SAFETY  AND  PUBLIC  HEALTH  PROJECTS  (OF 
2019.10467) 

29.884,00 

Total  

3.618.376,90 

The table below shows the service contracts signed by Chafea in 2019: 

Objective: 

1 

Amount committed 
in EUR 

Thematic priority 

2019 71 06 

2019 71 05 

2017 71 07  

Total objective 
Objectives' 
description: 
Thematic priority 

1.1  Cost-effective  promotion  and  prevention 
measures in  line, in  particular, with  the Union 
strategies on alcohol and nutrition 

Mapping  Member  States’  fiscal  measures  and 
pricing  policies  applied  to  food,  non-alcoholic 
drinks and alcoholic beverages 

Support to Member States in reducing alcohol-
related harm 
Food 
amended 

reformulation 

initiatives, 

contract 

1.5 

Tobacco legislation 

User reference 

Title 

2019 71 01 

2019 71 02 
2019 71 03 
2019 71 07 
2019 71 08 

Studies  supporting  the  Commission  report  on 
the  application  of  Directive  2014/40  on 
tobacco  products  (TPD)  under  SANTE  FWC 
SANTE/2016/A1/039 

Work carried out to provide services to support 
the assessment of flavours in tobacco products 
(4  SCs  under  Chafea/2016/Health/36  Tobacco 
flavours) 

Objective: 

2 

72 

247 995.00 

1 399 014.00 

110 989,50 

1 757 998,50 

Amount committed 

179 995.00 

28 000.00 
30 000.00 
115 000.00 
135 800.00 

488 795, 00 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Objectives' 
description: 
Thematic priority 

Protect  Union  citizens  from  serious  cross-
border health threats 
2.2  Support  capacity-building  against  health 
threats  in  Member  States,  including,  where 
appropriate,  cooperation  with  neighbouring 
countries (…) 

User reference 

Title 

2019 72 01 

Total objective 

and 

Options 
the 
development  of  a  common  EU  citizens 
vaccination card  

recommendations 

for 

Objectives:  

3 and 4  

Amount committed 

2 220 000.00 

2 220 000.00 

Objective’s 
description:  

Thematic priorities:  

to 

efficient 

innovative, 

Contribute 
sustainable health systems 
Facilitate  access  to  better  and  safer  healthcare 
for Union citizens 
3.2. and 4.1.  

and 

User reference 

Title  

2019 73 02  

Technical  assistance  to  the  National  Contact 
Points  for  e-Health  (NCPeH),  to  support  the 
exchange  of  data  through  the  e-Health  Digital 
Service Infrastructure 

Objective:  

3 

Amount committed 

804 720.00 

Objective’s 
description: 
Thematic priority: 

2019 104 04 

2019 104 07 

to 

and 

efficient 

innovative, 

Contribute 
sustainable health systems 
3.6  Actions  required  by  or  contributing  to  the 
implementation  of  Union  legislation  in  the 
field  of  medical  devices,  medicinal  products 
and cross-border healthcare. 
Development  of  the  future  EUDAMED  - 
helpdesk, 
training  and  quality  assurance 
function  (under  FWC  CHAFEA-2017-AGRI-
06 Lot 4) 

Translations,  info  campaigns,  publications  etc. 
related 
(under  FWC 
CHAFEA-2017-AGRI-06 Lot 4) 

to  medical  devices 

73 

762 965.00 

530 630.00 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total  

Objective: 

3 

1 293 595.00 

Objective’s 
description: 
Thematic priority: 

to 

and 

efficient 

innovative, 

to  contribute 

Contribute 
sustainable health systems 
3.7 Foster a health information and knowledge 
system 
to  evidence-based 
decision-making,  including  the  use  of  existing 
instruments, 
further  development,  where 
appropriate, of standardised health information 
and tools for monitoring health, collection and 
analysis of health data, the wide dissemination 
of the results of the Programme, and support to 
the Scientific Committees set up in accordance 
with Decision 2008/721/EC. 

User reference 

Title 

2019 73 03 

in  an 

International 
Amenable  mortality 
perspective: 
for 
study 
Feasibility 
Methodological  improvements  (under  SANTE 
FWC SANTE/2016/A1/039) 

Total objective 

Objective: 

4 

Amount committed 

88 250.00  

2 186 565.85 

Objective’s 
description: 
Thematic priority: 

2019 74 05 

2019 74 06 

Facilitate  access  to  better  and  safer  healthcare 
for Union citizens 
4.1  Support  the  establishment  of  a  system  of 
European  reference  networks  for  patients  with 
conditions  requiring  highly  specialised  care 
and  a  particular  concentration  of  resources  or 
expertise, as in the case of rare diseases, on the 
basis  of  criteria 
to  be  established  under 
Directive 2011/24/EU.  
European  Reference  Networks  capacity  and 
knowledge sharing through short term mobility 
and exchanges of healthcare professionals 

Development  of  an  integrated  assessment, 
quality 
monitoring, 
evaluation 
the 
improvement  system  (AMEQuIS)  for 
European Reference Networks  

and 

1 985 125.00 

850 826.00 

74 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thematic priority: 

4.4  In  line  with  the  Action  Plan  against  the 
rising  threats  from  antimicrobial  resistance, 
improve  the  prudent  use  of  antimicrobial 
agents  and  reduce  the  practices  that  increase 
antimicrobial resistance 

User reference 

Title 

2019 74 01 

2019 74 09 

Total objective 

EU networking and support for reference 
laboratory functions for antimicrobial 
resistance/ 1 

EU  networking  and  support  for  reference 
laboratory 
antimicrobial 
resistance/ Salmonella and Campylobacte 

functions 

for 

Thematic priority 

HORIZONTAL  

User reference 

Title 

SC 2019 70 01 

SC 2019 70 02 

2019 102 03 
2019 102 05 
2019 102 09 

2019 74 02 
2019 74 04 
2019 74 05 

Total horizontal 

Expert meetings under FWC 
Chafea/2018/Health/03 (GDPR mapping and 
expert consultation) 

meetings 
Expert 
Chafea/2018/Health/03 
analysis) 

under 
(GDPR 

– 

FWC 
legal 

Dissemination  activities  (3  SCs  under  FWC 
CHAFEA-2017-AGRI-06 Lot 2) 

Chronic disease dissemination day 
Zagreb information and dissemination day 
Conference on falsified medicine, Poland 

Horizontal DG Sante:  

Thematic priority  Horizontal 

75 

Amount committed 

2 490 757.00 

1 300 000.00 

6 626 708.00 

Amount committed 

422 336.00 

167 575.00 

173 702.49 
20 177.60 
50 314.03 

14 999,81 
5 297, 26 
14 827,51  

869 230,00 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Title 

Amount committed 

SC  7  -  DB  -    DOMAIN  CONSULTANT 
HEALTH 
EUROPEAN 
MEDICINAL PRODUCTS (EMP) 

FOR 

90.043,00 

OF  655  -  CONSULTANCY  FOR  THE 
MAINTENANCE  OF  AV  &  C 
INSTALLATIONS  DG  SANTE 
(OF 
2019.58709) 

1.000,00 

-  KD 

SC  3518 
-  APPLICATION 
DEVELOPER  FOR  SHAREPOINT  (OF 
2019.58735) 

8.000,00 

-  KD 

SC  3518 
-  APPLICATION 
DEVELOPER  FOR  SHAREPOINT  (OF 
2019.58735) 

8.000,00 

SC  9049  -  EM  -  PROJECT  MANAGER 
FOR  FOOD  SAFETY  AND  HEALTH 
PROJECTS 

23.530,00 

SC  9049  -  EM  -  PROJECT  MANAGER 
FOR  FOOD  SAFETY  AND  HEALTH 
PROJECTS 

17.000,00 

SC  9049  -  EM  -  PROJECT  MANAGER 
FOR  FOOD  SAFETY  AND  HEALTH 
PROJECTS 

15.071,20 

OF 1008973 - QLIK MAINTENANCE 

3.000,00 

-  AL 

SC  10541 
-  APPLICATION 
ARCHITECT  FOR  HEALTH  AND 
FOOD SAFETY PROJECTS 

15.633,30 

OF  3644  -  RENEWAL  SUBSCRIPTION 
TO LICENSES AND SOFTWARES 

12.000,00 

-  RD 

SC  12416 
-  APPLICATION 
ARCHITECT  FOR  PH  AND  FF 
PROJECTS 

14.920,70 

-  AA 

SC  12313 
-  APPLICATION 
ARCHITECT  (LUX)  PH  AND  F&F 
PROJECTS 

53.800,00 

SC  12313 
-  APPLICATION 
ARCHITECT  (LUX)  PH  AND  F&F 

-  AA 

11.226,00 

76 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROJECTS 

SC  11972  -  PS  -  PROJECT  MANAGER 
FOR PUBLIC HEALTH PROJECTS  

18.416,60 

SC 254 - OM - DOMAIN CONSULTANT 
FOR PH PROJECTS TM/LUX 

34.033,07 

SC 254 - OM - DOMAIN CONSULTANT 
FOR PH PROJECTS TM/LUX 

30.000,00 

SC 254 - OM - DOMAIN CONSULTANT 
FOR PH PROJECTS TM/LUX 

36.127,33 

SC 13628 - APPLICATION ARCHITECT 
FOR SANTE POLICIES 

15.000,00 

-  DC 

-  TECHNOLOGY 
SC  13990 
EXPERT  FOR  QUALITY  ASSURANCE 
HEALTH  AND 
SAFETY 
PROJECTS 

FOOD 

26.662,48 

SC 358 - JBS - DOMAIN CONSULTANT 
FOR  ANALYTICAL  AND  SCIENTIFIC 
EXPERTISE  IN  HEALTH  TM/BXL  - 
PXE 

100.000,00 

SC  15033  -  BV  -  PROJECT  MANAGER 
FOR EHDSI AND ERN 

8.374,00 

- 

1578 

-  BK 

SC 
SECURITY 
OPERATIONS  CENTRE  ANALYST  
FOR  HEALTH  AND  FOOD  SAFETY 
PROJECTS 

- 

1578 

-  BK 

SECURITY 
SC 
OPERATIONS  CENTRE  ANALYST  
FOR  HEALTH  AND  FOOD  SAFETY 
PROJECTS 

6.000,00 

7.537,59 

SC 316 - MK - DOMAIN CONSULTANT 
FOR EHEALTH AND EHDS PROJECTS 

20.000,00 

02 - SC AV0062 - VIDEO ON E-
HEALTH - MOD MT + MOD FDI 

82 715,00 

DIR F - 17.0301 - 
REIMBURSEMENT OF EXPERTS 
FOR JOINT ASSESSMENTS ON 
MEDICAL DEVICES – COMPL 

213 000,00 

77 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Grand total 

871 090,27  

7.6 Other actions 
EUR 7 438 839,29 was committed for other actions in 2019.  

Other actions  cover  contributions  paid  by the EU as  a  member of the  European Observatory on 

Health Systems and Policies and the administrative agreements with the European Commission’s 

Joint  Research  Centre.  They  also  cover  the  cost  of  the  cross  sub-delegations  with  Eurostat  for 

morbidity statistics and the European health interview surveys (EHIS), the costs of medical device 

coordination group (MDGG) meetings (e.g. special indemnities paid to experts for participating in 

meetings,  work  on  scientific  opinions  and  advice  on  health  systems)  and  costs  related  to 

international cooperation on veterinary medicines. 

The table below provides more information on ‘other actions’.  

Financial instrument  Chafea other actions by objective 

Objective: 
Objectives' 
description: 
Thematic priority: 

User reference 

3 
3. Contribute to innovative, efficient and sustainable 
health systems 
3.7. Foster a health information and knowledge system 
to contribute to evidence-based decision-making 
Title 

2019 51 01 

Total 

Objectives: 
Objectives' 
description: 
Thematic priority: 
User reference 

HP-PJ-2019 
HP-SGA-2019 
HP-JA-2019 
HP-JA-2019 
F.Y.F.A project 
738157 
Total 

Membership contribution to European Observatory on 
HCS & policies 

1-4 
Related to all programme objectives 

5.16. Expert evaluators 
Title 

Evaluation call for proposals project grants 
Evaluation OG/SGA 2019 
Quality assurance workshop JA 2019 
Technical review of Joint Actions  
Review interim report 

78 

Amount 
committed 
in EUR 

Amount 
committed  

500 000.00 

500.000.00 

Amount 
committed 
55 280.00 
35 894.37 
6 768.00 
73 920.00 
3 384.00  

175 246.37 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chafea – total 
committed for other 
actions 

Financial 
Instrument 

Objective: 
Objectives' 
description: 

Thematic 
priority: 

DG SANTE service contracts by objective 

1 
1.  Promote  health,  prevent  diseases  and  foster  supportive 
environments  for  healthy  lifestyles  taking  into  account  the 
'health in all policies' principle 
1.1/1.4/4.2 
Cost-effective  promotion  and  prevention  measures  in  line, 
in  particular,  with  the  Union  strategies  on  alcohol  and 
nutrition 
Support cooperation and networking in the Union in relation 
to  preventing  and  improving  the  response  to  chronic 
diseases 
Support  Member  States,  patient  organisations  and 
stakeholders  by  coordinated  action  at  Union  level  in  order 
to effectively help patients affected by rare diseases. 

User 
reference 

Title 

C4 - 17.0301 - AA N°35501 -HQ HIP II HEALTHCARE 
QUALITY, HEALTH INFO & PROMOTION 
C3 - 17.0301 - AA N°35665 -HQ HIP II HEALTHCARE 
QUALITY, HEALTH INFO & PROMOTION –
VACCINATION 
2019-51855 - ESTAT CONTRACT 2019.0084 - ESTATSS 
1-000082 - FWC 07112.2016.003-2017.018 -  SOGETI 
LUXEMBOURG SA - F.5 
2019-54001 - ESTAT CONTRACT 2019.0317 - ESTATSS 
1-000081 - FWC 07112.2016.003-2017.018 - SOGETI 
LUXEMBOURG SA - F.4 

Total 

1.5 Tobacco legislation 

B2 - SI2.819339 - 17.030100 AA WITH JRC N° 35674 - 
TECHNICAL SUPPORT TO THE IMPLEMENTATION OF 
THE TOBACCO PRODUCTS DIRECTIVE 

Grand total 

Objective 3 

3.4  Provide  expertise  and  share  good  practices  to  assist 

79 

675 246,37 

Amount 
committed in 
EUR 

Amount 
committed 

3 570 000.00 

1 000 000.00 

145 610.00 

289 605,00 
5 005 215,00 

100 000,00 
5 105 215,00 

 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Member States undertaking health system reforms 

UNIT B1 - 17.030100 - EXPERT PANEL ON INVESTING IN 
HEALTH  -  SPECIAL  INDEMNITIES  FOR  EXPERTS  - 
COMPL 

300 000,00 

B1  -  SI2.804177  -  SANTE2019  /B1/001  -  ORGANISATION 
OF 6 HEAIRINGS OF THE EXPERT PANEL OF EFFECTIVE 
WAYS OF INVESTING IN HEALTH  

79200,00 

B1  -  17.030100  -  EXPERT  PANEL  ON  EFFECTIVE  WAYS 
OF INVESTING IN HEALTH CONFERENCE ON 08/11/2019- 
AMEX 

28654,3 

Total 

407 854,30 

3.6  Implementation  of  Union  legislation  in  the  field  of 
medical  devices,  medicinal  products  and  cross-border 
healthcare 

GROW/D4  -  MEETINGS  OF  THE  MEDICAL  DEVICES 
COORDINATION  GROUP  (MDCG)    COVERING  TRAVEL 
EXPENSES OF PARTICIPANTS - 2019 

240000,00 

B5  -  19  -  SI2.803848  -  JOINT  AUDIT  PROGRAMME  ON 
GOOD MANUFACTURING PRACTICE 

85000,00 

ICH MEETINGS - REIMBURSEMENT OF EXPERTS 

80000,00 

B5  -  SANTE/2019/B5/004  -  17.030100  -  STAKEHOLDER 
EVENT  ON  EVALUATION  OF  ORPHAN  AND 
PAEDIATRIC REGULATIONS - COMPL 

32408,46 

F5  -  SI2.810152  -  17.0301  -  REIMBURSEMENT  OF 
PHARMACEUTICAL 
ACTIVE 
EXPERTS 
INGREDIENTS:  SYSTEM 
IN  NON-EU 
COUNTRIES. 

INSPECTIONS 

ON 

ICH AMSTERDAM 01 TO 06 JUNE 

UNIT  B3  -  17.030100  -  SERVICES  FOR  STAKEHOLDER 
EVENT  ON  EVALUATION  OF  ORPHAN  AND 
PAEDIATRIC LEGISLATION 

- 

17.030100 

B5 
EVALUATION  OF  ORPHAN  AND 
REGULATIONS - AMEX 

-  STAKEHOLDER  EVENT  ON 
PAEDIATRIC 

30000,00 

6897,74 

6000,00 

4 723,1 

ICH TOKYO 24 AU 31 MARS  

3 100,00 

80 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total 

Total 

Total 

Total objectif 

Grand total 

ICH USA 30 OCT TO 04 NOV 

3.7  Foster  a  health  information  and  knowledge  system  to 
contribute to evidence-based decision-making 

ICH SINGAPORE 16 TO 20 NOVEMBER 

2 394,32 

490 523,62 

80 000,00 

80 000,00  

3.7/2.4 Foster a health information and knowledge system to 
contribute to evidence-based decision-making 

C2  -  17.030100/19/801516  -  SCIENTIFIC  COMMITTEES 
AND PROVISION OF TARGUETED RISK ASSESSMENT IN 
CASE  OF  A  CHEMICAL  AND  ENVIRONMENTAL 
INCIDENT OF CROSS BORDER RELEVANCE - COMPL 

420 000,00 

B5  - SI2.813150 - ICH AND  IPPR MEMBERSHIP FEE FOR 
2020 -  

260000 

760 000,00 

1 658 377,92  

6 763 592,92 

81 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. DETAILED OVERVIEW OF THE REPORTING YEAR 2019 

8.1 Funding per thematic priority and financial instrument 

Objective: 

1 

1. Promote health, prevent diseases and foster supportive environments for healthy lifestyles taking into account the 'health in all policies' principle 

Chafea 
projects 
grants by 
objective 

Chafea ERN 
actions 
SGAs under 
FPA by 
objective 

Chafea 
operating 
grants by 
objective 

Chafea joint 
actions by 
objective 

Chafea direct 
grant 
agreements 
by objective 

Chafea 
presidency 
conferences 
by 
objective 

Chafea service 
contracts by 
objective 

SANTE service 
contracts by 
objective 

Chafea other 
actions by 
objective 

SANTE other 
actions by 
objective 

Total 

0.00 

0.00 

2,191,232.60 

6,000,000.00 

3,300,000.00 

100,000.00 

1,757,998.50 

0.00 

0.00 

5,005,215.00 

18,354,446.10 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

638,186.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

638,186.00 

0.00 

0.00 

774,178.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

774,178.00 

Objectives' 
description: 

Third health 
programme 
Thematic 
priorities 

1.1 Cost-effective 
promotion and 
prevention 
measures on 
alcohol and 
nutrition… 
1.2 Drugs-related 
health damage, 
information and 
prevention 
1.3 Support 
effective 
responses to 
communicable 
diseases, 
HIV/AIDS, 
tuberculosis and 
hepatitis 

1.4 Chronic 
diseases, cancer, 
age-related 
diseases and 
neurodegenerativ
e diseases 

82 

 
 
 
 
 
 
 
 
 
 
 
 
0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

488,795.00 

396,900.00 

0.00 

100,000.00 

985,695.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

3,603,596.60 

6,000,000.00 

3,300,000.00 

100,000.00 

2,246,793.50 

396,900.00 

0.00 

5,105,215.00 

20,752,505.10 

1.5. Tobacco 
legislation 

1.6 Foster a 
health 
information and 
knowledge 
system to 
contribute to 
evidence-based 
decision-making 
Total 

Objective: 

2 

Objectives' 
description: 
Third health 
programme 
Thematic priorities 

2.1 Improve risk 
assessment and close 
gaps in risk 
assessment 
capacities… 
2.2 Support capacity-
building against 
health threats in 
Member States 
Total 

Objective: 

Objectives' 
description: 

2. Protect Union citizens from serious cross-border health threats 

Chafea 
projects 
grants by 
objective 

Chafea ERN 
actions SGAs 
under FPA 
by objective 

Chafea 
operating 
grants by 
objective 

Chafea joint 
actions by 
objective 

Chafea 
direct grant 
agreements 
by 
objective 

Chafea 
presidency 
conferences by 
objective 

Chafea 
service 
contracts by 
objective 

SANTE service 
contracts by 
objective 

Chafea other 
actions by 
objective 

SANTE other 
actions by 
objective 

Total 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

4,992,837.00 

0.00 

0.00 

2,220,000.00 

845,793.32 

0.00 

0.00 

8,058,630.32 

0.00 

0.00 

0.00 

4,992,837.00 

0.00 

0.00 

2,220,000.00 

845,793.32 

0.00 

0.00 

8,058,630.32 

3 

3. Contribute to innovative, efficient and sustainable health systems 

83 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Third health 
programme 
Thematic priorities 

Chafea 
projects grants 
by objective 

Chafea ERN 
actions 
SGAs under 
FPA by 
objective 

Chafea 
operating 
grants by 
objective 

Chafea joint 
actions by 
objective 

Chafea direct 
grant 
agreements by 
objective 

Chafea 
presidency 
conferences 
by objective 

Chafea service 
contracts by 
objective 

SANTE 
service 
contracts by 
objective 

Chafea 
other 
actions by 
objective 

SANTE other 
actions by 
objective 

Total 

3.1 Support voluntary 
cooperation between 
Member States on 
health technology 
assessment… 

3.2 Promote the 
voluntary uptake of 
health innovation and 
e-Health  
3.3 Support the 
sustainability of the 
health workforce  

3.4. Provide expertise 
and share good 
practices to assist 
Member States 
undertaking health 
system reforms … 
3.6 Implementation of 
Union legislation in 
the field of medical 
devices, medicinal 
products and cross-
border health care 

3.7. Foster a health 
information and 
knowledge system to 
contribute to 
evidence-based 
decision-making 
Total 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

804,720.00 

0.00 

0.00 

0.00 

804,720.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

3,999,226.00 

0.00 

0.00 

0.00 

0.00 

0.00 

407,854.30 

4,407,080.30 

0.00 

0.00 

200,640.00 

0.00 

0.00 

0.00 

1,293,595.85 

4,338,071.00 

0.00 

490,523.62 

6,322,830.47 

0.00 

0.00 

0.00 

0.00 

2,450,000.00 

0.00 

88,250.00 

140,162.00 

500,000.00 

760,000.00 

3,938,412.00 

0.00 

0.00 

200,640.00 

3,999,226.00 

2,450,000.00 

0.00 

2,186,565.85 

4,478,233.00 

500,000.00 

1,658,377.92 

15,473,042.77 

84 

 
 
 
 
Objective: 

4 

Objectives' 
description: 
Third health 
programme 
Thematic priorities 

4.1 Support the 
establishment of a 
system of European 
reference networks  
4.2 Coordinated action 
at Union level to 
effectively help 
patients affected by 
rare diseases 
4.3 Strengthen 
collaboration on 
patient safety and 
quality of health care 
4.4 Improve the 
prudent use of 
antimicrobial agents 
and reduce the 
practices that increase 
antimicrobial 
resistance 

4.5 Implementation of 
Union legislation in the 
fields of human tissues 
and cells, blood, 
human organs, medical 
devices, medicinal 
products, and patients’ 
rights in cross-border 
health care 
Total 

4. Facilitate access to better and safer healthcare for Union citizens 

Chafea 
projects grants 
by objective 

Chafea ERN 
actions SGAs 
under FPA 
by objective 

Chafea 
operating 
grants by 
objective 

Chafea joint 
actions by 
objective 

Chafea direct 
grant 
agreements by 
objective 

Chafea 
presidency 
conferences 
by objective 

Chafea Call 
for tenders 
by objective 

SANTE 
calls for 
tender by 
objective 

Chafea 
other 
actions by 
objective 

SANTE 
other actions 
by objective 

Total 

3,787,146.39 

0.00 

0.00 

0.00 

0.00 

0.00 

2,835,951.00 

0,00 

0.00 

0.00 

6,623,097.39 

0.00 

0.00 

1,315,547.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

1,315,547.00 

0.00 

0.00 

0.00 

0.00 

0,00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

1,987,001.00 

0.00 

0.00 

0.00 

0.00 

0.00 

3,790,757.00 

0.00 

0.00 

0.00 

5,777,758.00 

0.00 

0.00 

314,500.00 

0.00 

0.00 

13,687.15 

0.00 

0.00 

0.00 

0.00 

328,187.15 

5,774,147.39 

0.00 

1,630,047.00 

0.00 

0.00 

13,687.15 

6,626,708.00 

0.00 

0.00 

0.00 

14,044,589.54 

85 

 
 
 
 
 
 
 
 
 
 
 
 
 
Objectives: 

5. Other actions or expenditures 

Objectives' description: 

5. IT / dissemination / Prizes (Horizontal, other actions related to all objectives)  

Third health 
programme  
Thematic priorities 

Chafea projects 
grants by 
objective 

Chafea ERN 
actions SGAs 
under FPA by 
objective 

Chafea 
operating 
grants by 
objective 

Chafea joint 
actions by 
objective 

Chafea 
direct 
grant 
agreements 
by 
objective 

Chafea 
presidency 
conferences 
by 
objective 

Chafea 
calls for 
tender by 
objective 

SANTE calls 
for tender by 
objective 

Chafea other 
actions by 
objective 

SANTE other 
actions by 
objective 

Total 

3.1 Prizes 

4.1.5 Dissemination

5.16. Expert evaluators  

5. Horizontal/ 
ICT/dissemination 

Total 

, 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

300,000.00 

0.00 

625,035.58 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

300,000.00 

625,035.58 

175,246.37 

0.00 

175,246.37 

0.00 

244,194.12 

3,318,376.90 

0.00 

871,090.27 

4,433,661.29 

0.00 

869,229.70 

3,618,376.90 

175,246.37 

871,090.27 

5,533,943.24 

TOTAL ACTIONS COMMITTED BY CHAFEA UNDER AWP 2019 

TOTAL ACTIONS COMMITTED BY DG SANTE UNDER AWP 2019 

TOTAL COMMITTED                                         

46 888 723,23 

16,973,986.41 

63 862 709,74 

86